Materiały źródłowe

• #1 Oligodendroglioma: Types, Causes, Symptoms, Treatment Strategies, and 2025 Breakthroughs – OncoDaily

  https://oncodaily.com/oncolibrary/cancer-types/oligodendroglioma

  The diagnosis of oligodendroglioma involves a combination of clinical evaluation, neuroimaging, histopathology, and molecular testing. Accurate diagnosis is essential because treatment decisions and prognosis are strongly influenced by both the tumors histologic grade and its molecular profile. […] The diagnostic process often begins when patients present with seizures, headaches, or neurological symptoms. A detailed neurological examination and symptom history guide the next steps. […] Magnetic Resonance Imaging (MRI) is the preferred imaging modality: T2-weighted and FLAIR sequences typically show a hyperintense, infiltrative lesion. Contrast-enhanced T1-weighted images may show no enhancement (in low-grade tumors) or heterogeneous enhancement (in higher-grade tumors). Calcifications, common in oligodendrogliomas, are better seen on CT scans.

• #2 Oligodendroglioma – Symptoms, Diagnosis, TreatmentSecond Opinion IconGroup 9Second Opinion IconGroup 49

  https://www.barrowneuro.org/condition/oligodendroglioma/

  Oligodendroglioma diagnosis often requires a combination of tests, imaging studies, biopsy, and occasionally more invasive procedures to be as accurate as possible. Usually, doctors seek to identify two specific genetic mutations in an oligodendroglioma diagnosis: the 1p/19q codeletion, a particular change in the tumor cells’ chromosomes, and an IDH mutation. […] The most common diagnostic tests for oligodendroglioma include: […] Physical and neurological exam: First, your provider will review your symptoms, medical history, and any risk factors you may have. Symptoms like headaches, seizures, or neurological deficits may prompt a further investigation. Next, a neurological examination will check your coordination, reflexes, strength, and other sensory functions. […] Magnetic Resonance Imaging (MRI): The most common test for diagnosing brain tumors, an MRI uses strong magnets and radio waves to provide detailed brain images to determine a tumor’s location, size, and characteristics. In imaging studies, oligodendrogliomas often show a “fried egg” appearance and may have areas of calcification.

• #3 Oligodendroglioma: Types, Causes, Symptoms, Treatment Strategies, and 2025 Breakthroughs – OncoDaily

  https://oncodaily.com/oncolibrary/cancer-types/oligodendroglioma

  The diagnosis of oligodendroglioma involves a combination of clinical evaluation, neuroimaging, histopathology, and molecular testing. Accurate diagnosis is essential because treatment decisions and prognosis are strongly influenced by both the tumors histologic grade and its molecular profile. […] The diagnostic process often begins when patients present with seizures, headaches, or neurological symptoms. A detailed neurological examination and symptom history guide the next steps. […] Magnetic Resonance Imaging (MRI) is the preferred imaging modality: T2-weighted and FLAIR sequences typically show a hyperintense, infiltrative lesion. Contrast-enhanced T1-weighted images may show no enhancement (in low-grade tumors) or heterogeneous enhancement (in higher-grade tumors). Calcifications, common in oligodendrogliomas, are better seen on CT scans.

• #4 Oligodendroglioma – Diagnosis and treatment – Mayo Clinic

  https://www.mayoclinic.org/diseases-conditions/oligodendroglioma/diagnosis-treatment/drc-20576750

  Tests and procedures used to diagnose oligodendroglioma include: […] During a neurological exam, you’re asked about your signs and symptoms. Your vision, hearing, balance, coordination, strength and reflexes are checked. […] Imaging tests can help determine where the brain tumor is and its size. MRI is often used to diagnose brain tumors. […] A biopsy is a procedure to remove a small sample of tissue from the tumor for testing. […] The tissue sample goes to a lab for testing. Tests can show what types of cells are involved. Special tests can show detailed information about the tumor cells. […] Your care team uses this information to create a treatment plan.

• #5 Oligodendroglioma – Symptoms, Diagnosis, TreatmentSecond Opinion IconGroup 9Second Opinion IconGroup 49

  https://www.barrowneuro.org/condition/oligodendroglioma/

  Oligodendroglioma diagnosis often requires a combination of tests, imaging studies, biopsy, and occasionally more invasive procedures to be as accurate as possible. Usually, doctors seek to identify two specific genetic mutations in an oligodendroglioma diagnosis: the 1p/19q codeletion, a particular change in the tumor cells’ chromosomes, and an IDH mutation. […] The most common diagnostic tests for oligodendroglioma include: […] Physical and neurological exam: First, your provider will review your symptoms, medical history, and any risk factors you may have. Symptoms like headaches, seizures, or neurological deficits may prompt a further investigation. Next, a neurological examination will check your coordination, reflexes, strength, and other sensory functions. […] Magnetic Resonance Imaging (MRI): The most common test for diagnosing brain tumors, an MRI uses strong magnets and radio waves to provide detailed brain images to determine a tumor’s location, size, and characteristics. In imaging studies, oligodendrogliomas often show a “fried egg” appearance and may have areas of calcification.

• #6 Diagnosing and Treating Oligodendrogliomas | Neurological Surgery

  https://neurosurgery.weillcornell.org/condition/oligodendroglioma/diagnosing-and-treating-oligodendrogliomas

  An oligodendroglioma is usually diagnosed after an individual notices symptoms and has been referred to a neurologist, a doctor who specializes in diseases of the central nervous system. […] A diagnosis of this brain tumor begins with a thorough physical exam during which a neurologist will ask about symptoms such as seizures, persistent headaches, vomiting, or other indications of pressure inside the skull. […] If the neurologist suspects a brain tumor, imaging tests and other diagnostic tests will be ordered to confirm and provide details about the tumor type, size, location, and speed of growth. […] One of the most important diagnostic tests for an oligodendroglioma is a biopsy, which will be done once an oligodendroglioma is suspected on imaging. […] This is because current research suggests the importance of identifying particular gene changes or biomarkers (molecules) to confirm oligodendrogliomas.

• #7 Oligodendroglioma | Brain Tumor Center | Stanford Medicine

  https://med.stanford.edu/brain-tumor/conditions/glioma/oligodendroglioma.html

  Oligodendrogliomas are tumors that arise within the central nervous system. […] Neurological examination, imaging, and tissue biopsy are the mainstays of glioma diagnosis. […] Since the symptoms caused by oligodendroglioma can be present with other illnesses, a careful evaluation is necessary to make a diagnosis. […] A thorough evaluation of the nervous system includes assessment of: mental status (awareness, memory), cranial nerves (nerves responsible for eye movement, taste, facial expressions), speech (speaking and understanding), muscle strength and grip, sensory function (ability to feel light touch, vibrations, temperature changes), balance and coordination, and reflexes. […] Magnetic resonance imaging (MRI) is often taken before and after the administration of intravenous contrast to visualize the tumor.

• #8 Oligodendroglioma | Brain Tumor Center | Stanford Medicine

  https://med.stanford.edu/brain-tumor/conditions/glioma/oligodendroglioma.html

  Oligodendrogliomas are tumors that arise within the central nervous system. […] Neurological examination, imaging, and tissue biopsy are the mainstays of glioma diagnosis. […] Since the symptoms caused by oligodendroglioma can be present with other illnesses, a careful evaluation is necessary to make a diagnosis. […] A thorough evaluation of the nervous system includes assessment of: mental status (awareness, memory), cranial nerves (nerves responsible for eye movement, taste, facial expressions), speech (speaking and understanding), muscle strength and grip, sensory function (ability to feel light touch, vibrations, temperature changes), balance and coordination, and reflexes. […] Magnetic resonance imaging (MRI) is often taken before and after the administration of intravenous contrast to visualize the tumor.

• #9 Oligodendroglioma: Symptoms, Treatment & Prognosis

  https://my.clevelandclinic.org/health/diseases/21191-oligodendroglioma

  Oligodendrogliomas are among the more treatable brain tumors and cancers. The treatment often involves multiple methods, including surgery, chemotherapy, and radiation therapy. […] A healthcare provider will diagnose oligodendroglioma using multiple methods, including a physical and neurological exam, diagnostic imaging, and a brain biopsy and pathology testing. […] Diagnostic imaging is especially important with oligodendrogliomas because it lets providers see inside your head. The scans that are most likely to help are computed tomography (CT) scans and magnetic resonance imaging (MRI) scans. […] A brain biopsy is a surgical procedure where a neurosurgeon will collect a tiny tumor sample. The tumor sample then goes to a lab for analysis. The analysis will look at the cells under a microscope for visible changes. The sample will also undergo genetic/molecular testing to determine if you have a 1p/19q chromosome co-deletion and an IDH mutation. If testing finds both, a healthcare provider can diagnose the tumor as an oligodendroglioma.

• #10 Oligodendroglioma – Symptoms, Diagnosis, TreatmentSecond Opinion IconGroup 9Second Opinion IconGroup 49

  https://www.barrowneuro.org/condition/oligodendroglioma/

  Oligodendroglioma diagnosis often requires a combination of tests, imaging studies, biopsy, and occasionally more invasive procedures to be as accurate as possible. Usually, doctors seek to identify two specific genetic mutations in an oligodendroglioma diagnosis: the 1p/19q codeletion, a particular change in the tumor cells’ chromosomes, and an IDH mutation. […] The most common diagnostic tests for oligodendroglioma include: […] Physical and neurological exam: First, your provider will review your symptoms, medical history, and any risk factors you may have. Symptoms like headaches, seizures, or neurological deficits may prompt a further investigation. Next, a neurological examination will check your coordination, reflexes, strength, and other sensory functions. […] Magnetic Resonance Imaging (MRI): The most common test for diagnosing brain tumors, an MRI uses strong magnets and radio waves to provide detailed brain images to determine a tumor’s location, size, and characteristics. In imaging studies, oligodendrogliomas often show a “fried egg” appearance and may have areas of calcification.

• #11 Oligodendroglioma – Diagnosis and treatment – Mayo Clinic

  https://www.mayoclinic.org/diseases-conditions/oligodendroglioma/diagnosis-treatment/drc-20576750

  Tests and procedures used to diagnose oligodendroglioma include: […] During a neurological exam, you’re asked about your signs and symptoms. Your vision, hearing, balance, coordination, strength and reflexes are checked. […] Imaging tests can help determine where the brain tumor is and its size. MRI is often used to diagnose brain tumors. […] A biopsy is a procedure to remove a small sample of tissue from the tumor for testing. […] The tissue sample goes to a lab for testing. Tests can show what types of cells are involved. Special tests can show detailed information about the tumor cells. […] Your care team uses this information to create a treatment plan.

• #12 Oligodendroglioma – Symptoms, Diagnosis, TreatmentSecond Opinion IconGroup 9Second Opinion IconGroup 49

  https://www.barrowneuro.org/condition/oligodendroglioma/

  Oligodendroglioma diagnosis often requires a combination of tests, imaging studies, biopsy, and occasionally more invasive procedures to be as accurate as possible. Usually, doctors seek to identify two specific genetic mutations in an oligodendroglioma diagnosis: the 1p/19q codeletion, a particular change in the tumor cells’ chromosomes, and an IDH mutation. […] The most common diagnostic tests for oligodendroglioma include: […] Physical and neurological exam: First, your provider will review your symptoms, medical history, and any risk factors you may have. Symptoms like headaches, seizures, or neurological deficits may prompt a further investigation. Next, a neurological examination will check your coordination, reflexes, strength, and other sensory functions. […] Magnetic Resonance Imaging (MRI): The most common test for diagnosing brain tumors, an MRI uses strong magnets and radio waves to provide detailed brain images to determine a tumor’s location, size, and characteristics. In imaging studies, oligodendrogliomas often show a “fried egg” appearance and may have areas of calcification.

• #13 Oligodendroglioma Imaging: Practice Essentials, Computed Tomography, Magnetic Resonance Imaging

  https://emedicine.medscape.com/article/342958-overview

  Because of the typically slow growth of oligodendrogliomas, the elapsed time between the initial symptoms and clinical diagnosis may vary from 1 week to 12 years. However, with MRI, this interval has been greatly reduced. Computed tomography (CT) scanning and magnetic resonance imaging (MRI) are complementary techniques for imaging oligodendrogliomas. […] Non-contrast-enhanced CT (NECT) is the initial imaging tool for nonspecific neurologic symptoms, typically because of the need to quickly identify intracranial hemorrhage, ischemic infarction, or other acute abnormality. On NECT, oligodendrogliomas typically appear as a hypodense or isodense peripheral mass. Coarse calcification is also a common finding, seen in up to 90% of cases. […] Low-grade and anaplastic oligodendrogliomas can be difficult to differentiate with standard MR imaging characteristics. Dynamic contrast-enhanced (DCE) MRI can assess tumor microvasculature and has demonstrated usefulness in predicting glioma grade and prognosis.

• #14 Oligodendroglioma: Types, Causes, Symptoms, Treatment Strategies, and 2025 Breakthroughs – OncoDaily

  https://oncodaily.com/oncolibrary/cancer-types/oligodendroglioma

  The diagnosis of oligodendroglioma involves a combination of clinical evaluation, neuroimaging, histopathology, and molecular testing. Accurate diagnosis is essential because treatment decisions and prognosis are strongly influenced by both the tumors histologic grade and its molecular profile. […] The diagnostic process often begins when patients present with seizures, headaches, or neurological symptoms. A detailed neurological examination and symptom history guide the next steps. […] Magnetic Resonance Imaging (MRI) is the preferred imaging modality: T2-weighted and FLAIR sequences typically show a hyperintense, infiltrative lesion. Contrast-enhanced T1-weighted images may show no enhancement (in low-grade tumors) or heterogeneous enhancement (in higher-grade tumors). Calcifications, common in oligodendrogliomas, are better seen on CT scans.

• #15 Oligodendroglioma Imaging: Practice Essentials, Computed Tomography, Magnetic Resonance Imaging

  https://emedicine.medscape.com/article/342958-overview

  Contrast enhancement is better seen with MRI than with CT scanning, especially with magnetization-transfer, T1-weighted spin-echo MRI sequences after gadolinium enhancement. The importance of contrast enhancement for the prognosis of these tumors has been emphasized because it seems to be the strongest negative factor affecting survival. […] In enhancing oligodendrogliomas, completely resecting enhancing tissue independently improves outcome, irrespective of histologic grade or genetic status. This finding supports aggressive resection and may impact treatment planning for patients with these tumors. […] The combined use of extensive molecular profiling and advanced MRI modalities may improve the accuracy of tumor grading, may provide prognostic information, and has the potential to influence treatment decisions.

• #16 Oligodendroglioma Imaging: Practice Essentials, Computed Tomography, Magnetic Resonance Imaging

  https://emedicine.medscape.com/article/342958-overview

  Contrast enhancement is better seen with MRI than with CT scanning, especially with magnetization-transfer, T1-weighted spin-echo MRI sequences after gadolinium enhancement. The importance of contrast enhancement for the prognosis of these tumors has been emphasized because it seems to be the strongest negative factor affecting survival. […] In enhancing oligodendrogliomas, completely resecting enhancing tissue independently improves outcome, irrespective of histologic grade or genetic status. This finding supports aggressive resection and may impact treatment planning for patients with these tumors. […] The combined use of extensive molecular profiling and advanced MRI modalities may improve the accuracy of tumor grading, may provide prognostic information, and has the potential to influence treatment decisions.

• #17 Oligodendroglioma | Expert Surgeon | Aaron Cohen-Gadol, MD

  https://www.aaroncohen-gadol.com/en/patients/glioma/types/oligodendroglioma

  How Is Oligodendroglioma Diagnosed? […] After a comprehensive history and physical examination, imaging of the brain and spinal cord can identify potential tumors. Computerized tomography (CT) scans and magnetic resonance imaging (MRI) are often used to identify the size and location of the tumor. CT scans use a series of x-rays to create a multi-dimensional image of the brain. MRI uses magnetic fields instead of radiation to create a similar image for evaluation. […] Other imaging studies may be necessary if recurrent tumor is suspected, and radiation change versus true tumor needs to be diagnosed.

• #18 Diagnosing and Treating Oligodendrogliomas | Neurological Surgery

  https://neurosurgery.weillcornell.org/condition/oligodendroglioma/diagnosing-and-treating-oligodendrogliomas

  In addition, it may predict how an individual will respond to different treatments, which will assist in planning appropriate and effective next steps. […] Since oligodendrogliomas are the focus of much research, learning specifics about the composition of the brain tumor can also indicate whether a person is suitable for a particular clinical trial. […] The 1p/19q test, as its called, is now used to evaluate treatments for people with certain types of tumors. […] A CT scanner relies on sophisticated X-ray devices connected to computers. […] An MRI uses a strong magnetic field and radio waves to create detailed images that reveal the location of a tumor and which parts of the brain are involved prior to surgery. […] Imaging tests of other parts of the body are not usually needed since oligodendrogliomas do not typically spread outside the central nervous system.

• #19 Oligodendroglioma Imaging: Practice Essentials, Computed Tomography, Magnetic Resonance Imaging

  https://emedicine.medscape.com/article/342958-overview

  Because of the typically slow growth of oligodendrogliomas, the elapsed time between the initial symptoms and clinical diagnosis may vary from 1 week to 12 years. However, with MRI, this interval has been greatly reduced. Computed tomography (CT) scanning and magnetic resonance imaging (MRI) are complementary techniques for imaging oligodendrogliomas. […] Non-contrast-enhanced CT (NECT) is the initial imaging tool for nonspecific neurologic symptoms, typically because of the need to quickly identify intracranial hemorrhage, ischemic infarction, or other acute abnormality. On NECT, oligodendrogliomas typically appear as a hypodense or isodense peripheral mass. Coarse calcification is also a common finding, seen in up to 90% of cases. […] Low-grade and anaplastic oligodendrogliomas can be difficult to differentiate with standard MR imaging characteristics. Dynamic contrast-enhanced (DCE) MRI can assess tumor microvasculature and has demonstrated usefulness in predicting glioma grade and prognosis.

• #20 Oligodendroglioma Imaging: Practice Essentials, Computed Tomography, Magnetic Resonance Imaging

  https://emedicine.medscape.com/article/342958-overview

  Perfusion-weighted MRI and positron emission tomography (PET) with amino acid tracers can provide complementary diagnostic information. In cases in which histopathologic diagnosis is based on partial tumor resection or biopsy, with subsequent risk for misclassification and undergrading, amino acid PET provides important additional diagnostic accuracy, since hot-spot areas generally represent the most malignant area of tumor. […] Oligodendrogliomas have the highest frequency of calcification of all brain tumors. CT scanning must be performed before and after the injection of contrast material to avoid missing the presence of calcifications. Typically, a round or oval, well-limited, and fairly large peripheral lesion is revealed. The tumor matrix is either hypoattenuating or isoattenuating and occasionally hyperattenuating because of tumoral hemorrhage or calcification.

• #21 Imaging of oligodendroglioma

  https://pmc.ncbi.nlm.nih.gov/articles/PMC4846213/

  Oligodendroglioma are glial tumours, predominantly occurring in adults. Their hallmark molecular feature is codeletion of the 1p and 19q chromosome arms, which is not only of diagnostic but also of prognostic and predictive relevance. […] For the initial diagnosis of oligodendroglioma, MRI and CT are complementary; MRI is superior to CT in assessing tumour extent and cortical involvement, whereas CT is most sensitive to calcification. Advanced and functional imaging techniques may aid in grading and assessing the molecular genotype as well as in differentiating between tumour recurrence and radiation necrosis, but so far no unequivocal method or combination of methods is available. […] The role of imaging in patients with oligodendroglioma falls into three main categories: (1) diagnostic work-up; (2) surgical and radiotherapy guidance; and (3) follow-up and treatment monitoring. Structural MRI is the workhorse imaging technique for all of these indications, while there is a small, complementary role for CT.

• #22 Final Diagnosis — Case 773

  https://path.upmc.edu/cases/case773/dx.html

  Radiologically, anaplastic oligodendroglioma presents as a calcified cortical-subcortical frontal lobe mass. […] Calcifications are seen in 90% of oligodendroglioma, (the most common glioma to present this feature); the calcifications can be nodular or gyriform. […] Anaplastic oligodendroglioma enhances much more commonly than low grade oligodendroglioma. […] The presence of solid enhancement, which is lacking in AVM, allowed the radiological presurgical diagnosis of high grade glioma. […] This case illustrates that highly vascular malignant gliomas can simulate vascular lesions by radiology and may require an angiogram for diagnosis.

• #23 Oligodendroglioma Imaging: Practice Essentials, Computed Tomography, Magnetic Resonance Imaging

  https://emedicine.medscape.com/article/342958-overview

  Because of the typically slow growth of oligodendrogliomas, the elapsed time between the initial symptoms and clinical diagnosis may vary from 1 week to 12 years. However, with MRI, this interval has been greatly reduced. Computed tomography (CT) scanning and magnetic resonance imaging (MRI) are complementary techniques for imaging oligodendrogliomas. […] Non-contrast-enhanced CT (NECT) is the initial imaging tool for nonspecific neurologic symptoms, typically because of the need to quickly identify intracranial hemorrhage, ischemic infarction, or other acute abnormality. On NECT, oligodendrogliomas typically appear as a hypodense or isodense peripheral mass. Coarse calcification is also a common finding, seen in up to 90% of cases. […] Low-grade and anaplastic oligodendrogliomas can be difficult to differentiate with standard MR imaging characteristics. Dynamic contrast-enhanced (DCE) MRI can assess tumor microvasculature and has demonstrated usefulness in predicting glioma grade and prognosis.

• #24 Oligodendroglioma Imaging: Practice Essentials, Computed Tomography, Magnetic Resonance Imaging

  https://emedicine.medscape.com/article/342958-overview

  Perfusion-weighted MRI and positron emission tomography (PET) with amino acid tracers can provide complementary diagnostic information. In cases in which histopathologic diagnosis is based on partial tumor resection or biopsy, with subsequent risk for misclassification and undergrading, amino acid PET provides important additional diagnostic accuracy, since hot-spot areas generally represent the most malignant area of tumor. […] Oligodendrogliomas have the highest frequency of calcification of all brain tumors. CT scanning must be performed before and after the injection of contrast material to avoid missing the presence of calcifications. Typically, a round or oval, well-limited, and fairly large peripheral lesion is revealed. The tumor matrix is either hypoattenuating or isoattenuating and occasionally hyperattenuating because of tumoral hemorrhage or calcification.

• #25 Oligodendroglioma Imaging: Practice Essentials, Computed Tomography, Magnetic Resonance Imaging

  https://emedicine.medscape.com/article/342958-overview

  Contrast enhancement is better seen with MRI than with CT scanning, especially with magnetization-transfer, T1-weighted spin-echo MRI sequences after gadolinium enhancement. The importance of contrast enhancement for the prognosis of these tumors has been emphasized because it seems to be the strongest negative factor affecting survival. […] In enhancing oligodendrogliomas, completely resecting enhancing tissue independently improves outcome, irrespective of histologic grade or genetic status. This finding supports aggressive resection and may impact treatment planning for patients with these tumors. […] The combined use of extensive molecular profiling and advanced MRI modalities may improve the accuracy of tumor grading, may provide prognostic information, and has the potential to influence treatment decisions.

• #26 Oligodendroglioma – StatPearls – NCBI Bookshelf

  https://www.ncbi.nlm.nih.gov/books/NBK559184/

  Oligodendrogliomas (OGs) are rare, slow-growing brain tumors that typically arise in the cerebral hemispheric white matter, most commonly in the frontal lobes. […] Definitive diagnosis relies on histopathological findings, including „fried egg” cells, a „chicken wire” vascular pattern, and molecular testing for isocitrate dehydrogenase mutations and 1p/19q codeletion. […] The diagnosis of OG is now determined using molecular markers, and the tumor must possess both an IDH1 or IDH2 mutation and 1p/19q codeletion to be classified as an OG. […] Histopathologic examination remains essential for definitive diagnosis, as radiographic imaging alone cannot distinguish OGs from other gliomas, especially low-grade tumors. […] These histopathological and molecular features facilitate accurate diagnosis and inform prognosis and therapeutic strategies.

• #27 Oligodendroglioma – Wikipedia

  https://en.wikipedia.org/wiki/Oligodendroglioma

  Oligodendrogliomas cannot currently be differentiated from other brain lesions solely by their clinical or radiographic appearance. As such, a brain biopsy is the only method of definitive diagnosis. […] Final diagnosis relies on biopsy and histopathologic examination of the tumor mass. […] The histopathologic grading of oligodendrogliomas is controversial. Currently, the most commonly used grading schema is based on the year 2007 World Health Organization (WHO) guidelines. An updated classification is in progress. […] The updated WHO guidelines published in 2007 recommends classifying such tumors for the time being as 'glioblastoma with oligodendroglioma component’. […] In the WHO 2021 CNS5 Classification, oligodendroglioma is named „Oligodendroglioma, IDH-mutant, and 1p/19q-codeleted”, and requires the presence of IDH1 or IDH2 mutations and the codeletion of chromosome 1p and 19q arms. […] Most larger cancer treatment centers routinely check for the deletion of 1p/19q as part of the pathology report for oligodendrogliomas.

• #28 Oligodendroglioma – Wikipedia

  https://en.wikipedia.org/wiki/Oligodendroglioma

  Oligodendrogliomas cannot currently be differentiated from other brain lesions solely by their clinical or radiographic appearance. As such, a brain biopsy is the only method of definitive diagnosis. […] Final diagnosis relies on biopsy and histopathologic examination of the tumor mass. […] The histopathologic grading of oligodendrogliomas is controversial. Currently, the most commonly used grading schema is based on the year 2007 World Health Organization (WHO) guidelines. An updated classification is in progress. […] The updated WHO guidelines published in 2007 recommends classifying such tumors for the time being as 'glioblastoma with oligodendroglioma component’. […] In the WHO 2021 CNS5 Classification, oligodendroglioma is named „Oligodendroglioma, IDH-mutant, and 1p/19q-codeleted”, and requires the presence of IDH1 or IDH2 mutations and the codeletion of chromosome 1p and 19q arms. […] Most larger cancer treatment centers routinely check for the deletion of 1p/19q as part of the pathology report for oligodendrogliomas.

• #29 Oligodendroglioma – StatPearls – NCBI Bookshelf

  https://www.ncbi.nlm.nih.gov/books/NBK559184/

  Oligodendrogliomas (OGs) are rare, slow-growing brain tumors that typically arise in the cerebral hemispheric white matter, most commonly in the frontal lobes. […] Definitive diagnosis relies on histopathological findings, including „fried egg” cells, a „chicken wire” vascular pattern, and molecular testing for isocitrate dehydrogenase mutations and 1p/19q codeletion. […] The diagnosis of OG is now determined using molecular markers, and the tumor must possess both an IDH1 or IDH2 mutation and 1p/19q codeletion to be classified as an OG. […] Histopathologic examination remains essential for definitive diagnosis, as radiographic imaging alone cannot distinguish OGs from other gliomas, especially low-grade tumors. […] These histopathological and molecular features facilitate accurate diagnosis and inform prognosis and therapeutic strategies.

• #30 Oligodendroglioma: Symptoms, Treatment & Prognosis

  https://my.clevelandclinic.org/health/diseases/21191-oligodendroglioma

  Oligodendrogliomas are among the more treatable brain tumors and cancers. The treatment often involves multiple methods, including surgery, chemotherapy, and radiation therapy. […] A healthcare provider will diagnose oligodendroglioma using multiple methods, including a physical and neurological exam, diagnostic imaging, and a brain biopsy and pathology testing. […] Diagnostic imaging is especially important with oligodendrogliomas because it lets providers see inside your head. The scans that are most likely to help are computed tomography (CT) scans and magnetic resonance imaging (MRI) scans. […] A brain biopsy is a surgical procedure where a neurosurgeon will collect a tiny tumor sample. The tumor sample then goes to a lab for analysis. The analysis will look at the cells under a microscope for visible changes. The sample will also undergo genetic/molecular testing to determine if you have a 1p/19q chromosome co-deletion and an IDH mutation. If testing finds both, a healthcare provider can diagnose the tumor as an oligodendroglioma.

• #31 Astrocytoma and oligodendroglioma | Neurosurgery Inselspital

  https://neurochirurgie.insel.ch/en/what-we-treat/brain-tumor/astrocytoma-and-oligodendroglioma

  With supramarginal resection, an additional safety margin of 1-2 cm is also removed, which has a positive influence on the probability of recurrence. […] If a tumor cannot be operated on because of its location in a functionally important center or because of its diffuse extension, at least a biopsy should be performed to examine the tissue and confirm the diagnosis. […] In a biopsy, a thin needle is inserted precisely into the tumor through a small hole and a tissue sample is taken. […] As soon as an exact diagnosis is available after the biopsy, the tumor is further treated with radiation and chemotherapy. […] The therapy of choice in the case of recurrence, i.e. a growing tumor, is again surgical removal. […] An international study has demonstrated that patients with WHO grade II glioma and the above risk factors benefit from chemotherapy in addition to radiation.

• #32 Oligodendroglioma – NEURO

  https://neurosurgerycnj.com/brain/oligodendroglioma/

  A biopsy of the tumor or suspicious tissue is taken before surgery and sent to a lab to analyze the types of cells and how aggressive (fast spreading) the cells are. A biopsy is performed using a needle to remove a small sample of the affected tissue. […] Other specialized tests of the tumor cells provide important information about the types of mutations (changes) the tumor cells have undergone. This data provides helpful information used to provide a prognosis (outcome and course of disease) and guide treatment options.

• #33 Oligodendroglioma Signs & Treatment | Baptist Health

  https://www.baptisthealth.com/care-services/conditions-treatments/oligodenroglioma

  Baptist Health is known for advanced, superior care in diagnosing and treating oligodendrogliomas. […] To determine if someone has an oligodendroglioma, we use advanced diagnostic procedures and technology to effectively diagnose, inform treatment and carefully monitor the condition. Diagnostic procedures can include: […] Depending on the location of the oligodendroglioma, a neurosurgeon may use a fine needle to draw out a small amount of tissue. It will be examined under a microscope to determine whether the tumor is cancerous. […] Magnetic resonance imaging (MRI) helps to locate and determine the size of an oligodendroglioma. […] If an oligodendroglioma is difficult to reach or located in a sensitive area, this procedure may be needed for a definite diagnosis. A surgeon will drill a small hole in the skull and use computer images to insert and guide a thin needle to remove a small amount of tumor tissue. The tissue, studied under a microscope, will help determine the type of tumor and treatment needed.

• #34 Diagnosis and Discussion – Case 1117 | Department of Pathology

  https://www.path.pitt.edu/diagnosis-and-discussion-case-1117

  Final Diagnosis: Oligodendroglioma, IDH-mutant and 1p/19q-codeleted, CNS WHO grade 3 […] Oligodendrogliomas most commonly present in the frontal lobe, with a median age of 43 at diagnosis, and classically present with seizures. Imaging will typically demonstrate a heterogenous mass with indistinct borders, occasionally cystic, with calcifications. On cytology preparations, oligodendrogliomas will demonstrate increased cellularity comprised of relatively monotonous cells with thin cytoplasm, round nuclei, with mild to moderate atypia. Histologically, oligodendrogliomas typically consist of glial tumor cells resembling nonneoplastic oligodendrocytes, with a fried egg appearance consisting of round nuclei and cytoplasmic clearing. Characteristically, they also exhibit chicken wire vasculature, microcalcifications, and microcysts.

• #35 Oligodendroglioma: Types, Causes, Symptoms, Treatment Strategies, and 2025 Breakthroughs – OncoDaily

  https://oncodaily.com/oncolibrary/cancer-types/oligodendroglioma

  A tissue sample is necessary for definitive diagnosis. Depending on tumor location and size, neurosurgeons may perform a biopsy or aim for maximal safe resection. The tumor is then evaluated under the microscope for features such as: Cellular uniformity with round nuclei, Fried egg appearance due to perinuclear halos, Delicate branching capillaries (chicken wire vascular pattern). […] The 2021 WHO CNS tumor classification requires confirmation of two molecular features for the diagnosis of oligodendroglioma: IDH1 or IDH2 mutation: Usually tested via immunohistochemistry or sequencing. 1p/19q codeletion: Confirmed using fluorescence in situ hybridization (FISH), PCR, or next-generation sequencing. If either of these is absent, the tumor is not considered an oligodendroglioma. […] Together, histologic and molecular features provide a layered diagnosis, aligning with WHO recommendations.

• #36 Diagnosis and Discussion – Case 1117 | Department of Pathology

  https://www.path.pitt.edu/diagnosis-and-discussion-case-1117

  Final Diagnosis: Oligodendroglioma, IDH-mutant and 1p/19q-codeleted, CNS WHO grade 3 […] Oligodendrogliomas most commonly present in the frontal lobe, with a median age of 43 at diagnosis, and classically present with seizures. Imaging will typically demonstrate a heterogenous mass with indistinct borders, occasionally cystic, with calcifications. On cytology preparations, oligodendrogliomas will demonstrate increased cellularity comprised of relatively monotonous cells with thin cytoplasm, round nuclei, with mild to moderate atypia. Histologically, oligodendrogliomas typically consist of glial tumor cells resembling nonneoplastic oligodendrocytes, with a fried egg appearance consisting of round nuclei and cytoplasmic clearing. Characteristically, they also exhibit chicken wire vasculature, microcalcifications, and microcysts.

• #37 Diagnosis and Discussion – Case 1117 | Department of Pathology

  https://www.path.pitt.edu/diagnosis-and-discussion-case-1117

  The WHO distinguishes two histologic grades of oligodendroglioma, CNS WHO grade 2 and CNS WHO grade 3, but the criteria for distinguishing between grades are not well defined. Some studies utilize a cutoff of at least 5 mitoses per 10 high power fields for grade 3 (or previously, anaplastic oligodendroglioma), along with high cellularity, marked cytologic atypia, microvascular proliferation, and necrosis. […] Greater than 90% of IDH mutations in gliomas are of the canonical IDH1 p.R132H missense mutation, which is commonly screened for using immunohistochemistry with an antibody designed to recognize the IDH1 R132H mutant protein. The remainder consists of less common IDH1 and IDH2 mutations. Oligodendrogliomas without the IDH1 p.R132H mutation are more likely than similar astrocytomas to harbor an IDH2 mutation, which typically involves the codon for R172.

• #38 Oligodendroglioma | The Brain Tumour Charity

  https://www.thebraintumourcharity.org/brain-tumour-diagnosis-treatment/types-of-brain-tumour-adult/oligodendroglioma/

  Oligodendrogliomas are diagnosed with 2 grades: grade 2 oligodendrogliomas, which grow slowly, and grade 3 oligodendrogliomas, which grow faster and are more likely to spread within the brain. […] Detecting these genetic alterations with biomarker testing is now essential for diagnosis and when evaluating which treatments will be used for people who are diagnosed with an oligodendroglioma. […] The test is useful in diagnosing oligodendrogliomas and, therefore, in making decisions about the most appropriate treatment for you. […] This test is useful in diagnosing oligodendrogliomas and in making decisions about the most appropriate treatment for you. […] For people with oligodendroglioma, the MGMT methylation test helps to predict how effective chemotherapy treatment is likely to be, although there are many other factors that also affect response to treatment. […] When found with 1p/19q co-deletion and IDH-mutant biomarkers, the TERT promoter mutation suggests a diagnosis of oligodendroglioma, and predicts greater benefit from chemotherapy and radiotherapy and longer survival, particularly in grade 2 and 3 gliomas.

• #39 Oligodendroglioma in Children

  https://healthlibrary.methodisthealthsystem.org/Library/DiseasesConditions/Adult/Spine/160,16

  Oligodendrogliomas may be diagnosed with MRI, CT scan, or both. […] Your child’s healthcare provider will ask about your child’s health history and symptoms. A physical exam with a neurological exam will be done. The neuro exam tests reflexes, muscle strength, eye and mouth movement, and coordination. Your child’s healthcare provider may refer your child to a pediatric cancer specialist (oncologist). Some of the tests that might be needed include: […] Part of diagnosing oligodendroglioma and deciding on treatment is learning more about the tumor. This process is called grading. Grading describes how much the cancer cells look like normal cells. Most tumors are graded on a scale of I (1) to IV (4). Oligodendroglioma are grouped as either grade II (2) or III (3). Grade II means that the cancer cells look a lot like normal cells and are likely to grow slowly. Grade III means that the cancer cells look very different and are fast growing. Grade III tumors are also called anaplastic oligodendrogliomas. Talk with your child’s healthcare provider about the grade of your child’s tumor and what it means.

• #40 Clinical features, diagnosis, and pathology of IDH-mutant, 1p/19q-codeleted oligodendrogliomas – UpToDate

  https://www.uptodate.com/contents/clinical-features-diagnosis-and-pathology-of-idh-mutant-1p-19q-codeleted-oligodendrogliomas

  Clinical features, diagnosis, and pathology of IDH-mutant, 1p/19q-codeleted oligodendrogliomas […] In the World Health Organization (WHO) classification of central nervous system tumors, oligodendroglial tumors are defined by molecular diagnostics to include only those diffuse gliomas harboring both a mutation in isocitrate dehydrogenase (IDH) type 1 or type 2 and codeletion of chromosomes 1p and 19q. […] The clinical manifestations, classification, pathologic classification, and molecular prognostic factors associated with IDH-mutant, 1p/19q-codeleted oligodendrogliomas (grades 2 and 3) will be reviewed here. […] Oligodendroglial tumors are rare tumors, constituting approximately 5 percent of all malignant primary tumors of the central nervous system.

• #41 Oligodendroglioma: Types, Causes, Symptoms, Treatment Strategies, and 2025 Breakthroughs – OncoDaily

  https://oncodaily.com/oncolibrary/cancer-types/oligodendroglioma

  A tissue sample is necessary for definitive diagnosis. Depending on tumor location and size, neurosurgeons may perform a biopsy or aim for maximal safe resection. The tumor is then evaluated under the microscope for features such as: Cellular uniformity with round nuclei, Fried egg appearance due to perinuclear halos, Delicate branching capillaries (chicken wire vascular pattern). […] The 2021 WHO CNS tumor classification requires confirmation of two molecular features for the diagnosis of oligodendroglioma: IDH1 or IDH2 mutation: Usually tested via immunohistochemistry or sequencing. 1p/19q codeletion: Confirmed using fluorescence in situ hybridization (FISH), PCR, or next-generation sequencing. If either of these is absent, the tumor is not considered an oligodendroglioma. […] Together, histologic and molecular features provide a layered diagnosis, aligning with WHO recommendations.

• #42 Let’s Talk About Oligodendroglioma

  https://braintumor.org/news/lets-talk-about-oligodendroglioma/

  For patients with oligodendroglioma, knowing their tumors biomarkers can mean the difference between an inaccurate diagnosis and a treatment plan tailored for the best possible outcome. Without biomarker testing, an oligodendroglioma could be misclassified as a different type of glioma, such as astrocytoma, which has a different prognosis and treatment approach. […] Two key biomarkers define oligodendrogliomas. […] The 1p/19q chromosomal co-deletion is the loss of the short (p) arm of chromosome 1 and the long (q) arm of chromosome 19. This co-deletion is required for a definitive oligodendroglioma diagnosis. […] Treatment for oligodendroglioma depends on several factors, including the tumors grade, size, location, and symptoms. […] When safe to do so, the primary treatment for oligodendroglioma is surgical resection to remove as much of the tumor as safely possible.

• #43 Oligodendroglioma | UCSF Brain Tumor Center

  https://braintumorcenter.ucsf.edu/condition/oligodendroglioma

  After obtaining a biopsy for tumor tissue analysis, oligodendrogliomas can be classified into grades based on how abnormal the tumor cells look. […] According to the 2016 WHO classification system, the diagnosis of oligodendroglioma and anaplastic oligodendroglioma requires the demonstration of several genetic mutations. Oligodendrogliomas have abnormal chromosomes that are missing sections of chromosomes 1p and 19q, called a 1p/19q co-deletion. […] If genetic testing capabilities are not available, or if genetic results are inconclusive, then the oligodendroglioma should be described as not otherwise specified (or NOS).

• #44 Oligodendroglioma | Brain (and spinal cord) tumours | Cancer Research UK

  https://www.cancerresearchuk.org/about-cancer/brain-tumours/types/oligodendroglioma

  Oligodendrogliomas are a rare type of brain tumour that develops from glial cells called oligodendrocytes. […] Doctors use a system to group (classify) brain tumours into different groups and types. The World Health Organisation (WHO) regularly update this system. The information in this page is based on the latest WHO classification of 2021. […] Your doctor looks to see if there are certain gene changes in the brain tumour cells. These tests are also called biomarkers or molecular studies. Your doctor uses these test results to decide what type of glioma you have. […] Your doctor diagnoses you with an oligodendroglioma if the glioma cells: have changes (mutations) in the IDH gene this is what IDH mutant means; are missing parts of chromosome 1 and chromosome 19 this is what 1p/19q co-deleted means.

• #45 Oligodendroglioma | Radiology Reference Article | Radiopaedia.org

  https://radiopaedia.org/articles/oligodendroglioma?embed_domain=external.radpair.com%252527%25255B0%25255D%252527%25255B0%25255D&lang=us

  Oligodendrogliomas are intracranial tumors that account for 5-25% of all gliomas and 5-10% of all primary intracranial neoplasms. […] They are characterized by IDH mutation and 1p19q codeletion and can be WHO CNS grade 2 or 3. […] As of 2016, however, with the update to the WHO classification of CNS tumors the diagnosis of oligodendroglioma is made by identifying a diffuse infiltrating glioma with IDH mutation and 1p19q codeletion. […] The reliance on molecular markers is, however, not foolproof. […] To formally make the diagnosis, a tumor must be shown to have both IDH-mutation and 1p19q co-deletion. […] By definition oligodendrogliomas should demonstrate IDH mutation (either IDH1 or IDH2) and 1p19q codeletion. […] Histological features are only one aspect of the diagnosis of oligodendroglioma.

• #46 Oligodendroglioma | Radiology Reference Article | Radiopaedia.org

  https://radiopaedia.org/articles/oligodendroglioma?lang=us

  Oligodendrogliomas are intracranial tumors that account for 5-25% of all gliomas and 5-10% of all primary intracranial neoplasms. […] They are characterized by IDH mutation and 1p19q codeletion and can be WHO CNS grade 2 or 3. […] As of 2016, however, with the update to the WHO classification of CNS tumors the diagnosis of oligodendroglioma is made by identifying a diffuse infiltrating glioma with IDH mutation and 1p19q codeletion. […] The reliance on molecular markers is, however, not foolproof. […] Histological features are only one aspect of the diagnosis of oligodendroglioma and to formally make the diagnosis, a tumor must be shown to have both IDH-mutation and 1p19q co-deletion. […] By definition oligodendrogliomas should demonstrate IDH mutation (either IDH1 or IDH2) and 1p19q codeletion. […] Treatment is surgical, with adjuvant radiotherapy and chemotherapy.

• #47 Oligodendroglioma – Symptoms, Diagnosis, TreatmentSecond Opinion IconGroup 9Second Opinion IconGroup 49

  https://www.barrowneuro.org/condition/oligodendroglioma/

  Genetic and molecular testing: Genetic testing for 1p/19q codeletion and IDH mutation is critical in distinguishing oligodendrogliomas from other gliomas and helping to guide the best treatments. The 1p/19q codeletion marker, present in all oligodendrogliomas, often means the tumor will respond better to certain types of chemotherapy and radiation. […] Additional genetic and molecular tests, such as TERT promoter mutation and MGMT promoter methylation tests, may be done to confirm the extent of your oligodendroglioma and help further guide your diagnosis and treatment options.

• #48 Oligodendroglioma | The Brain Tumour Charity

  https://www.thebraintumourcharity.org/brain-tumour-diagnosis-treatment/types-of-brain-tumour-adult/oligodendroglioma/

  Oligodendrogliomas are diagnosed with 2 grades: grade 2 oligodendrogliomas, which grow slowly, and grade 3 oligodendrogliomas, which grow faster and are more likely to spread within the brain. […] Detecting these genetic alterations with biomarker testing is now essential for diagnosis and when evaluating which treatments will be used for people who are diagnosed with an oligodendroglioma. […] The test is useful in diagnosing oligodendrogliomas and, therefore, in making decisions about the most appropriate treatment for you. […] This test is useful in diagnosing oligodendrogliomas and in making decisions about the most appropriate treatment for you. […] For people with oligodendroglioma, the MGMT methylation test helps to predict how effective chemotherapy treatment is likely to be, although there are many other factors that also affect response to treatment. […] When found with 1p/19q co-deletion and IDH-mutant biomarkers, the TERT promoter mutation suggests a diagnosis of oligodendroglioma, and predicts greater benefit from chemotherapy and radiotherapy and longer survival, particularly in grade 2 and 3 gliomas.

• #49 Oligodendroglioma | The Brain Tumour Charity

  https://www.thebraintumourcharity.org/brain-tumour-diagnosis-treatment/types-of-brain-tumour-adult/oligodendroglioma/

  Oligodendrogliomas are diagnosed with 2 grades: grade 2 oligodendrogliomas, which grow slowly, and grade 3 oligodendrogliomas, which grow faster and are more likely to spread within the brain. […] Detecting these genetic alterations with biomarker testing is now essential for diagnosis and when evaluating which treatments will be used for people who are diagnosed with an oligodendroglioma. […] The test is useful in diagnosing oligodendrogliomas and, therefore, in making decisions about the most appropriate treatment for you. […] This test is useful in diagnosing oligodendrogliomas and in making decisions about the most appropriate treatment for you. […] For people with oligodendroglioma, the MGMT methylation test helps to predict how effective chemotherapy treatment is likely to be, although there are many other factors that also affect response to treatment. […] When found with 1p/19q co-deletion and IDH-mutant biomarkers, the TERT promoter mutation suggests a diagnosis of oligodendroglioma, and predicts greater benefit from chemotherapy and radiotherapy and longer survival, particularly in grade 2 and 3 gliomas.

• #50 Diagnosis and Discussion – Case 1117 | Department of Pathology

  https://www.path.pitt.edu/diagnosis-and-discussion-case-1117

  While IDH-mutant glial neoplasms share the commonality of IDH alterations, they can typically be differentiated by additional genetic alterations that tend to segregate with oligodendroglial and astrocytic differentiation. 1p/19q codeletions are seen in oligodendrogliomas, as was identified in this case, and TERT promoter mutations are common.

• #51 Oligodendroglioma | MedLink Neurology

  https://www.medlink.com/articles/oligodendroglioma

  Examination for allelic loss of 1p and 19q and for the presence of an IDH mutation can distinguish oligodendroglial tumors from dysembryoplastic neuroepithelial tumors or neurocytomas. […] After taking a full history and performing thorough physical and neurologic examinations, obtaining neuroimaging with MRI is the next step to establishing a preoperative diagnosis. […] A cortical-subcortical lesion located in the frontal or parietal lobe is typical. […] On CT, an oligodendroglioma may appear as a rounded hypo- or isodense white matter lesion with punctate hyperdense areas indicative of calcification. […] Though neuroimaging may appear typical for oligodendroglioma, histopathological analysis of adequate tissue sampling obtained by stereotactic biopsy or maximal safe resection is still mandatory for establishing a definitive diagnosis.

• #52 Oligodendroglioma | MedLink Neurology

  https://www.medlink.com/articles/oligodendroglioma

  A fully characterized oligodendroglioma is contingent on the presence of IDH mutation and 1p/19q codeletion. […] This is particularly relevant in the case of infiltrating gliomas that exhibit oligodendroglial and astrocytic morphology, for which a diagnosis of oligoastrocytoma was historically assigned. […] In general, molecular genetic analysis will favor either an astrocytic or oligodendroglial genetic profile, though a few cases of dual-genotype oligoastrocytoma have been reported.

• #53 Oligodendroglioma: Types, Causes, Symptoms, Treatment Strategies, and 2025 Breakthroughs – OncoDaily

  https://oncodaily.com/oncolibrary/cancer-types/oligodendroglioma

  A tissue sample is necessary for definitive diagnosis. Depending on tumor location and size, neurosurgeons may perform a biopsy or aim for maximal safe resection. The tumor is then evaluated under the microscope for features such as: Cellular uniformity with round nuclei, Fried egg appearance due to perinuclear halos, Delicate branching capillaries (chicken wire vascular pattern). […] The 2021 WHO CNS tumor classification requires confirmation of two molecular features for the diagnosis of oligodendroglioma: IDH1 or IDH2 mutation: Usually tested via immunohistochemistry or sequencing. 1p/19q codeletion: Confirmed using fluorescence in situ hybridization (FISH), PCR, or next-generation sequencing. If either of these is absent, the tumor is not considered an oligodendroglioma. […] Together, histologic and molecular features provide a layered diagnosis, aligning with WHO recommendations.

• #54 Clinical features, diagnosis, and pathology of IDH-mutant, 1p/19q-codeleted oligodendrogliomas – UpToDate

  https://www.uptodate.com/contents/clinical-features-diagnosis-and-pathology-of-idh-mutant-1p-19q-codeleted-oligodendrogliomas

  Clinical features, diagnosis, and pathology of IDH-mutant, 1p/19q-codeleted oligodendrogliomas […] In the World Health Organization (WHO) classification of central nervous system tumors, oligodendroglial tumors are defined by molecular diagnostics to include only those diffuse gliomas harboring both a mutation in isocitrate dehydrogenase (IDH) type 1 or type 2 and codeletion of chromosomes 1p and 19q. […] The clinical manifestations, classification, pathologic classification, and molecular prognostic factors associated with IDH-mutant, 1p/19q-codeleted oligodendrogliomas (grades 2 and 3) will be reviewed here. […] Oligodendroglial tumors are rare tumors, constituting approximately 5 percent of all malignant primary tumors of the central nervous system.

• #55 Oligodendroglioma | Brain (and spinal cord) tumours | Cancer Research UK

  https://www.cancerresearchuk.org/about-cancer/brain-tumours/types/oligodendroglioma

  Oligodendrogliomas are a rare type of brain tumour that develops from glial cells called oligodendrocytes. […] Doctors use a system to group (classify) brain tumours into different groups and types. The World Health Organisation (WHO) regularly update this system. The information in this page is based on the latest WHO classification of 2021. […] Your doctor looks to see if there are certain gene changes in the brain tumour cells. These tests are also called biomarkers or molecular studies. Your doctor uses these test results to decide what type of glioma you have. […] Your doctor diagnoses you with an oligodendroglioma if the glioma cells: have changes (mutations) in the IDH gene this is what IDH mutant means; are missing parts of chromosome 1 and chromosome 19 this is what 1p/19q co-deleted means.

• #56 Oligodendroglioma | Treatment & Management | Point of Care

  https://www.statpearls.com/point-of-care/26152

  Oligodendroglioma (OG) is a diffusely infiltrating glioma representing approximately 5% of all primary intracranial tumors. Historically, the OG was diagnosed by the histological appearance of the tumor. However, in 2016, the World Health Organization (WHO) changed the criteria for classifying central nervous system (CNS) tumors to include a phenotypic and genotypic analysis. […] The etiology of OGs is multifactorial, involving genetic, environmental, epigenetic, and cellular factors. Genetically, the hallmark codeletion of chromosomal arms 1p and 19q is diagnostic in 70% to 90% of cases and correlates with better prognosis and therapy responsiveness. […] Histopathologic examination remains essential for definitive diagnosis, as radiographic imaging alone cannot distinguish OGs from other gliomas, especially low-grade tumors. All patients with a tumor will require tissue sampling and histologic examination of that tissue for diagnosis. In 2016, the WHO changed the criteria for classifying CNS tumors to include phenotypic and genotypic analysis. The diagnosis of OG is now determined using molecular markers, and the tumor must possess both an IDH1 or IDH2 mutation and 1p/19q codeletion to be classified as an OG. […] The OG is defined by its IDH mutation and 1p/19q deletion status and several imaging features that suggest the presence of an OG as opposed to an astrocytoma that includes course calcification and cortical-subcortical location.

• #57 Oligodendroglioma | Radiology Reference Article | Radiopaedia.org

  https://radiopaedia.org/articles/oligodendroglioma?embed_domain=external.radpair.com%252527%25255B0%25255D%252527%25255B0%25255D&lang=us

  Oligodendrogliomas are intracranial tumors that account for 5-25% of all gliomas and 5-10% of all primary intracranial neoplasms. […] They are characterized by IDH mutation and 1p19q codeletion and can be WHO CNS grade 2 or 3. […] As of 2016, however, with the update to the WHO classification of CNS tumors the diagnosis of oligodendroglioma is made by identifying a diffuse infiltrating glioma with IDH mutation and 1p19q codeletion. […] The reliance on molecular markers is, however, not foolproof. […] To formally make the diagnosis, a tumor must be shown to have both IDH-mutation and 1p19q co-deletion. […] By definition oligodendrogliomas should demonstrate IDH mutation (either IDH1 or IDH2) and 1p19q codeletion. […] Histological features are only one aspect of the diagnosis of oligodendroglioma.

• #58 Oligodendroglioma | UCSF Brain Tumor Center

  https://braintumorcenter.ucsf.edu/condition/oligodendroglioma

  After obtaining a biopsy for tumor tissue analysis, oligodendrogliomas can be classified into grades based on how abnormal the tumor cells look. […] According to the 2016 WHO classification system, the diagnosis of oligodendroglioma and anaplastic oligodendroglioma requires the demonstration of several genetic mutations. Oligodendrogliomas have abnormal chromosomes that are missing sections of chromosomes 1p and 19q, called a 1p/19q co-deletion. […] If genetic testing capabilities are not available, or if genetic results are inconclusive, then the oligodendroglioma should be described as not otherwise specified (or NOS).

• #59 Oligodendrogliomas Diagnosis & Treatment – NYC | Columbia Neurosurgery in New York City

  https://www.neurosurgery.columbia.edu/patient-care/conditions/oligodendrogliomas

  Oligodendrogliomas are tumors that develop from a certain type of cell called oligodendroglial progenitor cells. […] At Columbia University Irving Medical Center/NewYork-Presbyterian Hospital, we specialize in diagnosing and surgically treating oligodendrogliomas. […] On scale of one to four, the World Health Organization grades tumors according to growth speed and ability to spread to nearby tissues. Depending on this grade, oligodendrogliomas are labeled either low- or high-grade. […] Most oligodendrogliomas are low-grade, slow-growing tumors, so they may be present for several years before being diagnosed. However, a low-grade tumor can progress and become high-grade if untreated. […] Oligodendrogliomas are not common tumors, making up only about four percent of tumors that arise from brain cells, and they rarely occur in the spinal cord.

• #60 Oligodendroglioma in Children

  https://healthlibrary.methodisthealthsystem.org/Library/DiseasesConditions/Adult/Spine/160,16

  Oligodendrogliomas may be diagnosed with MRI, CT scan, or both. […] Your child’s healthcare provider will ask about your child’s health history and symptoms. A physical exam with a neurological exam will be done. The neuro exam tests reflexes, muscle strength, eye and mouth movement, and coordination. Your child’s healthcare provider may refer your child to a pediatric cancer specialist (oncologist). Some of the tests that might be needed include: […] Part of diagnosing oligodendroglioma and deciding on treatment is learning more about the tumor. This process is called grading. Grading describes how much the cancer cells look like normal cells. Most tumors are graded on a scale of I (1) to IV (4). Oligodendroglioma are grouped as either grade II (2) or III (3). Grade II means that the cancer cells look a lot like normal cells and are likely to grow slowly. Grade III means that the cancer cells look very different and are fast growing. Grade III tumors are also called anaplastic oligodendrogliomas. Talk with your child’s healthcare provider about the grade of your child’s tumor and what it means.

• #61 Oligodendroglioma | The Brain Tumour Charity

  https://www.thebraintumourcharity.org/brain-tumour-diagnosis-treatment/types-of-brain-tumour-adult/oligodendroglioma/

  Oligodendrogliomas are diagnosed with 2 grades: grade 2 oligodendrogliomas, which grow slowly, and grade 3 oligodendrogliomas, which grow faster and are more likely to spread within the brain. […] Detecting these genetic alterations with biomarker testing is now essential for diagnosis and when evaluating which treatments will be used for people who are diagnosed with an oligodendroglioma. […] The test is useful in diagnosing oligodendrogliomas and, therefore, in making decisions about the most appropriate treatment for you. […] This test is useful in diagnosing oligodendrogliomas and in making decisions about the most appropriate treatment for you. […] For people with oligodendroglioma, the MGMT methylation test helps to predict how effective chemotherapy treatment is likely to be, although there are many other factors that also affect response to treatment. […] When found with 1p/19q co-deletion and IDH-mutant biomarkers, the TERT promoter mutation suggests a diagnosis of oligodendroglioma, and predicts greater benefit from chemotherapy and radiotherapy and longer survival, particularly in grade 2 and 3 gliomas.

• #62 Oligodendroglioma in Children

  https://healthlibrary.methodisthealthsystem.org/Library/DiseasesConditions/Adult/Spine/160,16

  Oligodendrogliomas may be diagnosed with MRI, CT scan, or both. […] Your child’s healthcare provider will ask about your child’s health history and symptoms. A physical exam with a neurological exam will be done. The neuro exam tests reflexes, muscle strength, eye and mouth movement, and coordination. Your child’s healthcare provider may refer your child to a pediatric cancer specialist (oncologist). Some of the tests that might be needed include: […] Part of diagnosing oligodendroglioma and deciding on treatment is learning more about the tumor. This process is called grading. Grading describes how much the cancer cells look like normal cells. Most tumors are graded on a scale of I (1) to IV (4). Oligodendroglioma are grouped as either grade II (2) or III (3). Grade II means that the cancer cells look a lot like normal cells and are likely to grow slowly. Grade III means that the cancer cells look very different and are fast growing. Grade III tumors are also called anaplastic oligodendrogliomas. Talk with your child’s healthcare provider about the grade of your child’s tumor and what it means.

• #63 Oligodendroglioma | Radiology Reference Article | Radiopaedia.org

  https://radiopaedia.org/articles/oligodendroglioma?embed_domain=external.radpair.com%252527%25255B0%25255D%252527%25255B0%25255D&lang=us

  Importantly, and unlike astrocytomas, oligodendrogliomas with necrosis and microvascular proliferation are considered only WHO grade 3 and not grade 4 tumors. […] Approximately 50% of oligodendrogliomas enhance: the degree of enhancement is extremely variable, ranging from no enhancement to strikingly vivid enhancement. […] The MRI appearances also vary depending on whether a histological diagnosis or a molecular definition is used. […] Oligodendrogliomas NOS, or those tumors that histologically show oligodendroglial features but are 1p/19q intact show more homogeneous signal on T1 and T2 images and have sharper borders than 'true’ oligodendroglioma, those with 1p/19q co-deletion. […] Survival statistics are primarily available for histologically defined oligodendrogliomas and tend to demonstrate 10 year-survival of approximately 50%.

• #64 Oligodendroglioma – Brain Tumour Foundation of Canada

  https://www.braintumour.ca/brain_tumour_types/oligodendroglioma/

  Oligodendroglioma accounts for approximately 2.5% of all primary brain tumours and 5-6% of all gliomas. The incidence of oligodendroglioma has significantly increased over the past years. […] Oligodendrogliomas can be identified by deficiencies in certain chromosomes named 1p and 19q. Genetic profiling of oligodendrogliomas provides a more accurate predictor of prognosis and treatment options than does standard pathology. […] Oligodendrogliomas are generally felt to be incurable using current treatments. However compared to the more common astrocytomas, they are slowly growing with prolonged survival. In one series, median survival times for oligodendrogliomas were 11.6 years for grade II and 3.5 years for grade III. However, such figures can be misleading since they do not factor in the types of treatment nor the genetic signature of the tumours.

• #65 What is an oligodendroglioma? | The Ottawa Hospital Foundation

  https://ohfoundation.ca/oligodendrogliomas/

  Oligodendrogliomas can be either grade II (slow growing) or grade III (fast growing/malignant). […] Diagnosis usually starts with a physical examination by a physician who will further discuss your symptoms and do testing to identify any concerning changes. They look at things like coordination, speech difficulties and vision or memory changes, followed by a brain scan (usually a CT scan and then an MRI), and finally surgery, which is the only definitive way to know what type of tumour it is. […] Patients with Oligodendroglioma have a higher survival rate than most other malignant brain tumours. […] Patients with grade II tumours are likely to live over 10 years after diagnosis but those patients with grade III tumours have a shorter life expectancy.

• #66 Oligodendroglioma | MedLink Neurology

  https://www.medlink.com/articles/oligodendroglioma

  Oligodendrogliomas are diffusely infiltrating chemoresponsive gliomas defined by the presence of mutated isocitrate dehydrogenase 1 (IDH1) or IDH2 and whole-arm chromosomal losses of 1p and 19q. […] The integration of genetic parameters IDH, ATRX, and 1p/19q has resulted in far fewer misdiagnoses, and in turn, it has improved correlations with prognosis and treatment response for diffuse gliomas as a group. […] The authors review the evolving approach to the diagnosis and management of this tumor. […] Definitive diagnosis can generally be made on histologic examination of sample tissue, though features of some tumors, such as pilocytic astrocytoma, central neurocytoma, dysembryoplastic neuroepithelial tumor, and ependymoma (particularly with clear cell histologic features), may resemble oligodendroglioma.

• #67 Oligodendroglioma – Symptoms, Types, Causes & Diagnosis

  https://www.ganeshdiagnostic.com/blog/oligodendroglioma-symptoms-types-causes-and-diagnosis

  Oligodendroglioma is the most significant oligodendroglioma differential diagnosis. As will be discussed below, conventional imaging cannot consistently distinguish between these cancers of different World Health Organization (WHO) grades. […] Imaging tests: Imaging examinations assist in locating and sizing the brain tumour. Brain tumours are frequently diagnosed using various magnetic resonance imaging (MRI) procedures. Computed tomography (CT) and positron emission tomography (PET) are two other imaging tests that may be performed. […] Anaplastic oligodendroglioma exhibits oedema, haemorrhage, cystic degeneration, and contrast enhancement more frequently than oligodendroglioma. Ring-like contrast enhancement, which is typically linked with glioblastoma, can occasionally be noticed. […] The grade of the tumour and the timing of the diagnosis both affect the oligodendroglioma patient’s life expectancy.

• #68 Oligodendroglioma | MedLink Neurology

  https://www.medlink.com/articles/oligodendroglioma

  Oligodendrogliomas are diffusely infiltrating chemoresponsive gliomas defined by the presence of mutated isocitrate dehydrogenase 1 (IDH1) or IDH2 and whole-arm chromosomal losses of 1p and 19q. […] The integration of genetic parameters IDH, ATRX, and 1p/19q has resulted in far fewer misdiagnoses, and in turn, it has improved correlations with prognosis and treatment response for diffuse gliomas as a group. […] The authors review the evolving approach to the diagnosis and management of this tumor. […] Definitive diagnosis can generally be made on histologic examination of sample tissue, though features of some tumors, such as pilocytic astrocytoma, central neurocytoma, dysembryoplastic neuroepithelial tumor, and ependymoma (particularly with clear cell histologic features), may resemble oligodendroglioma.

• #69 Oligodendroglioma Imaging: Practice Essentials, Computed Tomography, Magnetic Resonance Imaging

  https://emedicine.medscape.com/article/342958-overview

  Oligodendrogliomas are better defined on MRI than on CT scanning. Many oligodendrogliomas are peripherally situated, and the tumor usually involves the whole thickness of the cortex. MRI is particularly reliable for appreciating cortical involvement. The frontal lobes are most often involved, followed by the temporal, parietal, and occipital lobes. […] High-grade oligodendrogliomas may be difficult to differentiate from the more frequent glioblastoma multiforme. However, the presence of tumor calcification, a peripheral location, and the sometimes associated calvarial erosion may indicate an oligodendroglioma.

• #70 Oligodendroglioma | MedLink Neurology

  https://www.medlink.com/articles/oligodendroglioma

  Examination for allelic loss of 1p and 19q and for the presence of an IDH mutation can distinguish oligodendroglial tumors from dysembryoplastic neuroepithelial tumors or neurocytomas. […] After taking a full history and performing thorough physical and neurologic examinations, obtaining neuroimaging with MRI is the next step to establishing a preoperative diagnosis. […] A cortical-subcortical lesion located in the frontal or parietal lobe is typical. […] On CT, an oligodendroglioma may appear as a rounded hypo- or isodense white matter lesion with punctate hyperdense areas indicative of calcification. […] Though neuroimaging may appear typical for oligodendroglioma, histopathological analysis of adequate tissue sampling obtained by stereotactic biopsy or maximal safe resection is still mandatory for establishing a definitive diagnosis.

• #71 Imaging of oligodendroglioma

  https://pmc.ncbi.nlm.nih.gov/articles/PMC4846213/

  Oligodendroglioma are glial tumours, predominantly occurring in adults. Their hallmark molecular feature is codeletion of the 1p and 19q chromosome arms, which is not only of diagnostic but also of prognostic and predictive relevance. […] For the initial diagnosis of oligodendroglioma, MRI and CT are complementary; MRI is superior to CT in assessing tumour extent and cortical involvement, whereas CT is most sensitive to calcification. Advanced and functional imaging techniques may aid in grading and assessing the molecular genotype as well as in differentiating between tumour recurrence and radiation necrosis, but so far no unequivocal method or combination of methods is available. […] The role of imaging in patients with oligodendroglioma falls into three main categories: (1) diagnostic work-up; (2) surgical and radiotherapy guidance; and (3) follow-up and treatment monitoring. Structural MRI is the workhorse imaging technique for all of these indications, while there is a small, complementary role for CT.

• #72 Oligodendroglioma Imaging: Practice Essentials, Computed Tomography, Magnetic Resonance Imaging

  https://emedicine.medscape.com/article/342958-overview

  Oligodendroglioma is a well-differentiated, diffusely infiltrating tumor of adults that is typically located in the cerebral hemispheres and is predominantly composed of cells that morphologically resemble oligodendroglia. The hallmark molecular feature is deletion of the 1p and 19q chromosome arms. […] According to several studies, survival in patients with oligodendrogliomas is not correlated with tumor location or surgical removal. Rather, survival seems to be primarily correlated with the histologic features, clinical findings (age at onset, epilepsy vs deficit), and radiologic criteria (especially contrast enhancement and perfusion-weighted imaging). […] Because anaplastic oligoastrocytoma imaging findings mirror those of anaplastic oligodendroglioma, distinction cannot be reliably made on CT or MRI. The imaging features of the 1p/19q codeleted genotype that are considered typical of oligodendroglioma include indistinct tumor margin, heterogeneous signal intensity, and calcifications.

• #73 Imaging of oligodendroglioma

  https://pmc.ncbi.nlm.nih.gov/articles/PMC4846213/

  New enhancement in a previously non-enhancing, untreated tumour is suggestive of malignant transformation. […] Imaging features of the 1p/19q codeleted genotype are those traditionally considered typical of oligodendroglioma: indistinct tumour margin, heterogeneous signal intensity and calcifications. The added value of advanced imaging techniques in distinguishing codeleted from intact tumours is modest, showing increased perfusion and metabolism in codeleted tumours.

• #74 Oligodendroglioma Imaging: Practice Essentials, Computed Tomography, Magnetic Resonance Imaging

  https://emedicine.medscape.com/article/342958-overview

  Oligodendroglioma is a well-differentiated, diffusely infiltrating tumor of adults that is typically located in the cerebral hemispheres and is predominantly composed of cells that morphologically resemble oligodendroglia. The hallmark molecular feature is deletion of the 1p and 19q chromosome arms. […] According to several studies, survival in patients with oligodendrogliomas is not correlated with tumor location or surgical removal. Rather, survival seems to be primarily correlated with the histologic features, clinical findings (age at onset, epilepsy vs deficit), and radiologic criteria (especially contrast enhancement and perfusion-weighted imaging). […] Because anaplastic oligoastrocytoma imaging findings mirror those of anaplastic oligodendroglioma, distinction cannot be reliably made on CT or MRI. The imaging features of the 1p/19q codeleted genotype that are considered typical of oligodendroglioma include indistinct tumor margin, heterogeneous signal intensity, and calcifications.

• #75 Oligodendroglioma Imaging: Practice Essentials, Computed Tomography, Magnetic Resonance Imaging

  https://emedicine.medscape.com/article/342958-overview

  Oligodendrogliomas are better defined on MRI than on CT scanning. Many oligodendrogliomas are peripherally situated, and the tumor usually involves the whole thickness of the cortex. MRI is particularly reliable for appreciating cortical involvement. The frontal lobes are most often involved, followed by the temporal, parietal, and occipital lobes. […] High-grade oligodendrogliomas may be difficult to differentiate from the more frequent glioblastoma multiforme. However, the presence of tumor calcification, a peripheral location, and the sometimes associated calvarial erosion may indicate an oligodendroglioma.

• #76 Let’s Talk About Oligodendroglioma

  https://braintumor.org/news/lets-talk-about-oligodendroglioma/

  Due to the slow-growing nature of these tumors, patients may follow a watch and wait approach before treatment is recommended. […] In 2024, the U.S. Food and Drug Administration (FDA) approved vorasidenib for adults and pediatric patients (12+) with grade 2 astrocytoma or oligodendroglioma harboring an IDH1 or IDH2 mutation. This milestone marked the first-ever FDA-approved systemic therapy for these low-grade gliomas, offering patients a new option beyond traditional chemotherapy and radiation. […] Vorasidenib represents an additional option for doctors to manage these tumors. […] Oligodendrogliomas can develop anywhere in the brain but commonly occur in the frontal and temporal lobes. […] Seizures are one of the most common and often the first symptoms of oligodendroglioma. […] For people living with oligodendroglioma, routine MRIs and other medical scans are a necessary part of managing the disease.

• #77 Oligodendroglioma | Radiology Reference Article | Radiopaedia.org

  https://radiopaedia.org/articles/oligodendroglioma?embed_domain=external.radpair.com%252527%25255B0%25255D%252527%25255B0%25255D&lang=us

  Importantly, and unlike astrocytomas, oligodendrogliomas with necrosis and microvascular proliferation are considered only WHO grade 3 and not grade 4 tumors. […] Approximately 50% of oligodendrogliomas enhance: the degree of enhancement is extremely variable, ranging from no enhancement to strikingly vivid enhancement. […] The MRI appearances also vary depending on whether a histological diagnosis or a molecular definition is used. […] Oligodendrogliomas NOS, or those tumors that histologically show oligodendroglial features but are 1p/19q intact show more homogeneous signal on T1 and T2 images and have sharper borders than 'true’ oligodendroglioma, those with 1p/19q co-deletion. […] Survival statistics are primarily available for histologically defined oligodendrogliomas and tend to demonstrate 10 year-survival of approximately 50%.

• #78 Final Diagnosis — Case 773

  https://path.upmc.edu/cases/case773/dx.html

  Radiologically, anaplastic oligodendroglioma presents as a calcified cortical-subcortical frontal lobe mass. […] Calcifications are seen in 90% of oligodendroglioma, (the most common glioma to present this feature); the calcifications can be nodular or gyriform. […] Anaplastic oligodendroglioma enhances much more commonly than low grade oligodendroglioma. […] The presence of solid enhancement, which is lacking in AVM, allowed the radiological presurgical diagnosis of high grade glioma. […] This case illustrates that highly vascular malignant gliomas can simulate vascular lesions by radiology and may require an angiogram for diagnosis.

• #79 Imaging of oligodendroglioma

  https://pmc.ncbi.nlm.nih.gov/articles/PMC4846213/

  New enhancement in a previously non-enhancing, untreated tumour is suggestive of malignant transformation. […] Imaging features of the 1p/19q codeleted genotype are those traditionally considered typical of oligodendroglioma: indistinct tumour margin, heterogeneous signal intensity and calcifications. The added value of advanced imaging techniques in distinguishing codeleted from intact tumours is modest, showing increased perfusion and metabolism in codeleted tumours.

• #80 Oligodendroglioma — Low Grade Glioma Registry

  https://gliomaregistry.org/oligodendroglioma

  Regular MRI scans are recommended following the diagnosis of oligodendroglioma, generally at least once per year. Patients with seizures will need to be followed for their seizure medication. […] Prognosis means a prediction of outcome. This information is usually based on information gathered from groups of people with the same disease. It is important to remember these statistics are not individualized. […] Oligodendrogliomas are most common in adults and most often occur between the ages of 20-40. Although these tumors are found in both men and women, they tend to occur more often in men. Oligodendrogliomas are very rare in children under the age of 15.

• #81 Oligodendroglioma – American Brain Tumor Association | Learn More

  https://www.abta.org/tumor_types/oligodendroglioma/

  Oligodendrogliomas come from oligodendrocytes, one of the types of cells that make up the supportive, or glial, tissue of the brain. […] Biopsy is typically performed on tumors that are not accessible to confirm the diagnosis and help guide treatment. […] Regular MRI scans are recommended following the diagnosis of oligodendroglioma, generally at least once per year. […] A recurring oligodendroglioma may be treated with surgery, particularly when the time between initial diagnosis and recurrence is extended. In this way, the diagnosis can be updated to reflect any molecular changes that may have occurred over time, whether they be naturally occurring or associated with any treatments including radiation, chemotherapy, or immunotherapy. […] Molecular profiling is the detection of specific genes, proteins, or other molecules in a tumor. This information helps confirm tumor diagnosis, inform treatment options, and predict prognosis. […] Oligodendrogliomas are a type of glioma that have mutations in one of two genes called IDH1 and IDH2 and are missing the two chromosomal arms, 1p and 19q. These tumors are thus named Oligodendroglioma, IDH-mutant, and 1p/19q-codeleted.

• #82 Oligodendroglioma — Low Grade Glioma Registry

  https://gliomaregistry.org/oligodendroglioma

  Regular MRI scans are recommended following the diagnosis of oligodendroglioma, generally at least once per year. Patients with seizures will need to be followed for their seizure medication. […] Prognosis means a prediction of outcome. This information is usually based on information gathered from groups of people with the same disease. It is important to remember these statistics are not individualized. […] Oligodendrogliomas are most common in adults and most often occur between the ages of 20-40. Although these tumors are found in both men and women, they tend to occur more often in men. Oligodendrogliomas are very rare in children under the age of 15.

• #83 Oligodendroglioma | Expert Surgeon | Aaron Cohen-Gadol, MD

  https://www.aaroncohen-gadol.com/en/patients/glioma/types/oligodendroglioma

  How Is Oligodendroglioma Diagnosed? […] After a comprehensive history and physical examination, imaging of the brain and spinal cord can identify potential tumors. Computerized tomography (CT) scans and magnetic resonance imaging (MRI) are often used to identify the size and location of the tumor. CT scans use a series of x-rays to create a multi-dimensional image of the brain. MRI uses magnetic fields instead of radiation to create a similar image for evaluation. […] Other imaging studies may be necessary if recurrent tumor is suspected, and radiation change versus true tumor needs to be diagnosed.

• #84 Oligodendroglioma Prognosis | Brain Tumour Survival Rates

  https://www.thebraintumourcharity.org/brain-tumour-diagnosis-treatment/types-of-brain-tumour-adult/oligodendroglioma/oligodendroglioma-prognosis/

  Your doctor cannot be absolutely certain about what will happen to you following a diagnosis of an oligodendroglioma brain tumour. They can give you an estimate, based on your tumour type and current situation, but they may not be able to predict other factors, such as how well you might respond to treatment. This is why prognosis is often an ongoing process, revised at different stages in your journey. […] About 66 to 78% of people with a grade 2 oligodendroglioma survive for 5 years or more after diagnosis. […] A grade 3 oligodendroglioma is also called an anaplastic oligodendroglioma. About 30 to 38% of people with this type of tumour will survive for 5 years or more after they are diagnosed. […] It is important to remember that statistics and averages cannot tell you what will happen to you specifically.

• #85

  https://link.springer.com/article/10.1007/s00401-015-1424-1

  For nearly a century, the diagnosis and grading of oligodendrogliomas and oligoastrocytomas has been based on histopathology alone. […] Subsequently, this codeletion appeared to not only carry diagnostic, but also prognostic and predictive information, the latter aspect only recently resolved after carefully constructed clinical trials with very long follow-up times. […] It has therefore been suggested that complete 1p/19q codeletion be required for the diagnosis of canonical oligodendroglioma. […] This transition to an integrated morphological and molecular diagnosis may result in the disappearance of oligoastrocytoma as an entity, but brings new challenges as well. […] Meanwhile, smart integration of morphological and molecular information will lead to recognition of biologically much more uniform groups within the spectrum of diffuse gliomas and thereby facilitate tailored treatments for individual patients.

• #86 Oligodendroglioma – brain tumour | Macmillan Cancer Support

  https://www.macmillan.org.uk/cancer-information-and-support/brain-tumour/oligodendroglioma

  Your doctors need to find out as much as possible about the type, position and size of the tumour so they can plan your treatment. […] You will usually have brain scans to find out the exact position and size of the tumour. […] You may first have a brain CT scan first. You also usually have an MRI brain scan. […] Having an MRI scan is important as it can give more detailed information. […] There are different types of MRI scans. You may need to have more than 1 to ensure that your doctors have all of the information they need to make a diagnosis and guide any treatment. […] You may also have a biopsy, which involves an operation to take a sample of the tumour to test. […] A neuro-pathologist (doctor who specialises in examining brain tissue samples) looks at the tumour sample under a microscope. This is to find out how fast the tumour is likely to grow. Tests called molecular marker tests are also done on the sample to look for genetic changes (mutations) in the tumour cells.

• #87

  https://link.springer.com/article/10.1007/s00401-015-1424-1

  For nearly a century, the diagnosis and grading of oligodendrogliomas and oligoastrocytomas has been based on histopathology alone. […] Subsequently, this codeletion appeared to not only carry diagnostic, but also prognostic and predictive information, the latter aspect only recently resolved after carefully constructed clinical trials with very long follow-up times. […] It has therefore been suggested that complete 1p/19q codeletion be required for the diagnosis of canonical oligodendroglioma. […] This transition to an integrated morphological and molecular diagnosis may result in the disappearance of oligoastrocytoma as an entity, but brings new challenges as well. […] Meanwhile, smart integration of morphological and molecular information will lead to recognition of biologically much more uniform groups within the spectrum of diffuse gliomas and thereby facilitate tailored treatments for individual patients.

• #88 1p/19q Deletion in Oligodendrogliomas | Test Fact Sheet

  https://arupconsult.com/ati/1p19q-deletion-oligodendrogliomas

  1p/19q Deletion by FISH and IDH1 R132H Point Mutation by Immunohistochemistry with Reflex to IDH1 and IDH2 Mutation Analysis, Exon 4 […] Preferred initial test for the diagnosis of oligodendrogliomas […] Detect IDH1 or IDH2 mutation and 1p/19q codeletion, which are both necessary for a firm diagnosis of oligodendrogliomas […] Use when oligodendrogliomas are suspected […] Identification of the 1p/19q deletion is useful in differentiating oligodendrogliomas from astrocytomas and assists in the diagnosis and prognosis of both low- and high-grade oligodendrogliomas, as well as in predicting response to therapy. The 1p/19q deletion should not be used alone for diagnosis. […] Combined loss of chromosomal arms 1p and 19q is diagnostic for oligodendrogliomas […] Presence of codeletion establishes diagnosis of oligodendroglioma […] Effectively rules out diagnosis of oligodendroglioma […] Test should not be used alone for the diagnosis of malignancy.

• #89

  https://link.springer.com/article/10.1007/s00401-015-1424-1

  The high clinical relevance of 1p/19q loss became clear when this marker appeared to be associated with sensitivity to chemotherapy and improved outcome. […] Application of strict (as opposed to relaxed) histopathological criteria for recognition of oligodendrogliomas results in a higher correlation with 1p/19q codeleted tumors. […] The most promising markers for oligodendroglial tumors are briefly discussed below. […] In conclusion, after almost a century of a histopathologically based classification of CNS tumors, we are now experiencing the transition towards an integrated morphological and molecular definition of diffuse gliomas, with in some situations the clinical relevance of the molecular findings overriding the relevance of the histopathological diagnosis. […] It can be expected that in the updated WHO classification (publication of which is scheduled early in 2016) demonstration of (complete) 1p/19q codeletion will indeed be required for the diagnosis of canonical oligodendroglioma and that the (poorly reproducible) diagnosis of mixed gliomas will largely disappear.

• #90 Current diagnosis and treatment of oligodendroglioma in: Neurosurgical Focus Volume 12 Issue 2 (2002) Journals

  https://thejns.org/focus/view/journals/neurosurg-focus/12/2/foc.2002.12.2.3.xml

  The strategies used to diagnose and treat oligodendroglial tumors have changed significantly over the past decade. […] Because of tools such as magnetic resonance imaging, oligodendrogliomas are being diagnosed earlier, and they are being recognized more frequently histologically than in the past. […] Genetic analysis and positron emission tomography may provide data that supplement the standard diagnostic tools. […] Oligodendrogliomas are the first type of brain tumor for which molecular characterization gives important information. The most significant finding is that allelic losses on chromosomes 1p and 19q indicate a favorable response to chemotherapy. […] Molecular characterization of oligodendrogliomas may become a standard practice in the near future.

• #91 1p/19q Deletion in Oligodendrogliomas | Test Fact Sheet

  https://arupconsult.com/ati/1p19q-deletion-oligodendrogliomas

  1p/19q Deletion by FISH and IDH1 R132H Point Mutation by Immunohistochemistry with Reflex to IDH1 and IDH2 Mutation Analysis, Exon 4 […] Preferred initial test for the diagnosis of oligodendrogliomas […] Detect IDH1 or IDH2 mutation and 1p/19q codeletion, which are both necessary for a firm diagnosis of oligodendrogliomas […] Use when oligodendrogliomas are suspected […] Identification of the 1p/19q deletion is useful in differentiating oligodendrogliomas from astrocytomas and assists in the diagnosis and prognosis of both low- and high-grade oligodendrogliomas, as well as in predicting response to therapy. The 1p/19q deletion should not be used alone for diagnosis. […] Combined loss of chromosomal arms 1p and 19q is diagnostic for oligodendrogliomas […] Presence of codeletion establishes diagnosis of oligodendroglioma […] Effectively rules out diagnosis of oligodendroglioma […] Test should not be used alone for the diagnosis of malignancy.

• #92 Final Diagnosis — Case 773

  https://path.upmc.edu/cases/case773/dx.html

  Anaplastic oligodendroglioma (WHO III) is a highly cellular diffuse infiltrating glioma with histologic features of malignancy. […] Oligodendroglioma is made up of monotonous cells with well-defined borders and prominent clear cytoplasm („perinuclear halo”) surrounding hyperchromatic nuclei and resulting in a classic „fried-egg” appearance. […] The molecular genetic signature of oligodendrogliomas at the DNA level is combined 1p/19q loss, typically involving the entire chromosomal arm at both sites. Combined 1p/19q loss has been reported in 50% to 80% of cases carrying a diagnosis of oligodendroglioma, with frequencies as high as 90% when using strict diagnostic criteria. […] 1p/19q status is a predictive marker of response to PCV chemotherapy and is also a prognostic marker. […] Moreover, the presence of IDH1 mutations is present in high frequency in diffuse gliomas as oligodendroglioma. This mutation is a very significant prognostic factor in anaplastic oligodendroglioma, for overall survival but without evidence of a predictive significance for outcome to PCV chemotherapy.

• #93 Oligodendroglioma – Wikipedia

  https://en.wikipedia.org/wiki/Oligodendroglioma

  Oligodendrogliomas cannot currently be differentiated from other brain lesions solely by their clinical or radiographic appearance. As such, a brain biopsy is the only method of definitive diagnosis. […] Final diagnosis relies on biopsy and histopathologic examination of the tumor mass. […] The histopathologic grading of oligodendrogliomas is controversial. Currently, the most commonly used grading schema is based on the year 2007 World Health Organization (WHO) guidelines. An updated classification is in progress. […] The updated WHO guidelines published in 2007 recommends classifying such tumors for the time being as 'glioblastoma with oligodendroglioma component’. […] In the WHO 2021 CNS5 Classification, oligodendroglioma is named „Oligodendroglioma, IDH-mutant, and 1p/19q-codeleted”, and requires the presence of IDH1 or IDH2 mutations and the codeletion of chromosome 1p and 19q arms. […] Most larger cancer treatment centers routinely check for the deletion of 1p/19q as part of the pathology report for oligodendrogliomas.

• #94 Diagnosis and Discussion – Case 1117 | Department of Pathology

  https://www.path.pitt.edu/diagnosis-and-discussion-case-1117

  The WHO distinguishes two histologic grades of oligodendroglioma, CNS WHO grade 2 and CNS WHO grade 3, but the criteria for distinguishing between grades are not well defined. Some studies utilize a cutoff of at least 5 mitoses per 10 high power fields for grade 3 (or previously, anaplastic oligodendroglioma), along with high cellularity, marked cytologic atypia, microvascular proliferation, and necrosis. […] Greater than 90% of IDH mutations in gliomas are of the canonical IDH1 p.R132H missense mutation, which is commonly screened for using immunohistochemistry with an antibody designed to recognize the IDH1 R132H mutant protein. The remainder consists of less common IDH1 and IDH2 mutations. Oligodendrogliomas without the IDH1 p.R132H mutation are more likely than similar astrocytomas to harbor an IDH2 mutation, which typically involves the codon for R172.

• #95 Diagnosis and Discussion – Case 1117 | Department of Pathology

  https://www.path.pitt.edu/diagnosis-and-discussion-case-1117

  The WHO distinguishes two histologic grades of oligodendroglioma, CNS WHO grade 2 and CNS WHO grade 3, but the criteria for distinguishing between grades are not well defined. Some studies utilize a cutoff of at least 5 mitoses per 10 high power fields for grade 3 (or previously, anaplastic oligodendroglioma), along with high cellularity, marked cytologic atypia, microvascular proliferation, and necrosis. […] Greater than 90% of IDH mutations in gliomas are of the canonical IDH1 p.R132H missense mutation, which is commonly screened for using immunohistochemistry with an antibody designed to recognize the IDH1 R132H mutant protein. The remainder consists of less common IDH1 and IDH2 mutations. Oligodendrogliomas without the IDH1 p.R132H mutation are more likely than similar astrocytomas to harbor an IDH2 mutation, which typically involves the codon for R172.

• #96 Final Diagnosis — Case 773

  https://path.upmc.edu/cases/case773/dx.html

  Anaplastic oligodendroglioma (WHO III) is a highly cellular diffuse infiltrating glioma with histologic features of malignancy. […] Oligodendroglioma is made up of monotonous cells with well-defined borders and prominent clear cytoplasm („perinuclear halo”) surrounding hyperchromatic nuclei and resulting in a classic „fried-egg” appearance. […] The molecular genetic signature of oligodendrogliomas at the DNA level is combined 1p/19q loss, typically involving the entire chromosomal arm at both sites. Combined 1p/19q loss has been reported in 50% to 80% of cases carrying a diagnosis of oligodendroglioma, with frequencies as high as 90% when using strict diagnostic criteria. […] 1p/19q status is a predictive marker of response to PCV chemotherapy and is also a prognostic marker. […] Moreover, the presence of IDH1 mutations is present in high frequency in diffuse gliomas as oligodendroglioma. This mutation is a very significant prognostic factor in anaplastic oligodendroglioma, for overall survival but without evidence of a predictive significance for outcome to PCV chemotherapy.

• #97 Oligodendroglioma | The Brain Tumour Charity

  https://www.thebraintumourcharity.org/brain-tumour-diagnosis-treatment/types-of-brain-tumour-adult/oligodendroglioma/

  Oligodendrogliomas are diagnosed with 2 grades: grade 2 oligodendrogliomas, which grow slowly, and grade 3 oligodendrogliomas, which grow faster and are more likely to spread within the brain. […] Detecting these genetic alterations with biomarker testing is now essential for diagnosis and when evaluating which treatments will be used for people who are diagnosed with an oligodendroglioma. […] The test is useful in diagnosing oligodendrogliomas and, therefore, in making decisions about the most appropriate treatment for you. […] This test is useful in diagnosing oligodendrogliomas and in making decisions about the most appropriate treatment for you. […] For people with oligodendroglioma, the MGMT methylation test helps to predict how effective chemotherapy treatment is likely to be, although there are many other factors that also affect response to treatment. […] When found with 1p/19q co-deletion and IDH-mutant biomarkers, the TERT promoter mutation suggests a diagnosis of oligodendroglioma, and predicts greater benefit from chemotherapy and radiotherapy and longer survival, particularly in grade 2 and 3 gliomas.

• #98 Oligodendroglioma | The Brain Tumour Charity

  https://www.thebraintumourcharity.org/brain-tumour-diagnosis-treatment/types-of-brain-tumour-adult/oligodendroglioma/

  Oligodendrogliomas are diagnosed with 2 grades: grade 2 oligodendrogliomas, which grow slowly, and grade 3 oligodendrogliomas, which grow faster and are more likely to spread within the brain. […] Detecting these genetic alterations with biomarker testing is now essential for diagnosis and when evaluating which treatments will be used for people who are diagnosed with an oligodendroglioma. […] The test is useful in diagnosing oligodendrogliomas and, therefore, in making decisions about the most appropriate treatment for you. […] This test is useful in diagnosing oligodendrogliomas and in making decisions about the most appropriate treatment for you. […] For people with oligodendroglioma, the MGMT methylation test helps to predict how effective chemotherapy treatment is likely to be, although there are many other factors that also affect response to treatment. […] When found with 1p/19q co-deletion and IDH-mutant biomarkers, the TERT promoter mutation suggests a diagnosis of oligodendroglioma, and predicts greater benefit from chemotherapy and radiotherapy and longer survival, particularly in grade 2 and 3 gliomas.

• #99 Astrocytoma and oligodendroglioma | Neurosurgery Inselspital

  https://neurochirurgie.insel.ch/en/what-we-treat/brain-tumor/astrocytoma-and-oligodendroglioma

  The most common side effects of irradiation are fatigue, nausea, skin irritation, and hair loss. […] The typical genetic signature of diffuse astrocytoma with IDH mutation is an alteration in the p53 and ATRX genes. […] The genetic markers in low-grade gliomas are extremely important because tumors with a different growth behavior „hide” among them.

• #100 Oligodendroglioma | Brain Tumor Center | Stanford Medicine

  https://med.stanford.edu/brain-tumor/conditions/glioma/oligodendroglioma.html

  When the history, neurological examination, and images are concerning for an oligodendroglioma, the next step is to obtain diagnostic tissue. A tissue sample is required to establish the diagnosis and accurately classify the glioma. […] Pathologists use a microscope and special stains to identify the type of glial cell in the tumor biopsy. […] The presence of specific genetic markers (mutations) has been shown to be a reliable predictor of tumor behavior and treatment response. […] Pathologists also consider the cellular appearance and presence of genetic markers to assign a grade to the tumor. Grading is a prediction of how the cancer would behave without treatment.

• #101 Oligodendroglioma | Boston Children’s Hospital

  https://www.childrenshospital.org/conditions/oligodendroglioma

  Oligodendrogliomas are low-grade gliomas, a type of brain tumor, that arise from a type of cell called an oligodendrocyte. […] It is important to consult a physician for a formal diagnosis. Possible diagnostic procedures for an oligodendroglioma may include: […] Your child’s physician will determine a specific course of treatment based on several factors. […] Children and adolescents with oligodendroglioma are treated at Dana-Farber/Boston Children’s Cancer and Blood Disorders Center through our Glioma Program, one of the largest and most experienced pediatric glioma programs in the world, and part of the Brain Tumor Center.

• #102 Oligodendrogliomas and Oligoastrocytomas | Glasser Brain Tumor Center, NJ

  https://ahs.atlantichealth.org/care/brain-tumor-center/brain-tumor-treatment/oligodendrogliomas-oligoastrocytomas.html

  Oligodendrogliomas and oligoastrocytomas are diagnosed through a neurological examination followed by a computed tomography (CT) or magnetic resonance imaging (MRI) scan of the brain. MRI scans are usually performed with contrast dye to help identify the tumors size, location and type. […] An exact diagnosis can only be confirmed following a stereotactic biopsy or surgical removal of the tumor. Tissue analysis by a neuropathologist defines the diagnosis and genetic profile of the tumor. […] Our team will complete a diagnosis and molecular profile of each tumor, which is individually reviewed by our multidisciplinary tumor board. Together, our experts recommend the best personalized and targeted treatment options.

• #103

  https://www.advocatehealth.com/health-services/brain-spine-institute/brain-spine-tumors/oligodendroglioma

  Oligodendroglioma tumors are currently divided into two types. The type of cell is determined through biomarker testing of cancer cells and what the cells look like under a microscope. […] To reach a diagnosis for your potential oligodendroglioma tumor, your doctor is likely to refer you to an experienced neuro-oncologist or neurosurgeon. These specialists will gather your medical history, ask about the duration of your symptoms and perform a physical. The physical includes tests that look for neurological signs of problems related to your potential oligodendroglioma symptoms. […] Imaging tests such as an MRI or CT may be ordered to gain more information about the location and size of any potential tumor. […] Combining the IDH mutation, chromosome changes and the appearance of the cells confirms the oligodendroglioma diagnosis. Finding differences in details like IDH mutation also helps your health care team choose the most effective treatments and medications.

• #104 Oligodendroglioma – brain tumour | Macmillan Cancer Support

  https://www.macmillan.org.uk/cancer-information-and-support/brain-tumour/oligodendroglioma

  Your doctors need to find out as much as possible about the type, position and size of the tumour so they can plan your treatment. […] You will usually have brain scans to find out the exact position and size of the tumour. […] You may first have a brain CT scan first. You also usually have an MRI brain scan. […] Having an MRI scan is important as it can give more detailed information. […] There are different types of MRI scans. You may need to have more than 1 to ensure that your doctors have all of the information they need to make a diagnosis and guide any treatment. […] You may also have a biopsy, which involves an operation to take a sample of the tumour to test. […] A neuro-pathologist (doctor who specialises in examining brain tissue samples) looks at the tumour sample under a microscope. This is to find out how fast the tumour is likely to grow. Tests called molecular marker tests are also done on the sample to look for genetic changes (mutations) in the tumour cells.

• #105 Oligodendrogliomas and Oligoastrocytomas | Glasser Brain Tumor Center, NJ

  https://ahs.atlantichealth.org/care/brain-tumor-center/brain-tumor-treatment/oligodendrogliomas-oligoastrocytomas.html

  Oligodendrogliomas and oligoastrocytomas are diagnosed through a neurological examination followed by a computed tomography (CT) or magnetic resonance imaging (MRI) scan of the brain. MRI scans are usually performed with contrast dye to help identify the tumors size, location and type. […] An exact diagnosis can only be confirmed following a stereotactic biopsy or surgical removal of the tumor. Tissue analysis by a neuropathologist defines the diagnosis and genetic profile of the tumor. […] Our team will complete a diagnosis and molecular profile of each tumor, which is individually reviewed by our multidisciplinary tumor board. Together, our experts recommend the best personalized and targeted treatment options.

• #106 Let’s Talk About Oligodendroglioma

  https://braintumor.org/news/lets-talk-about-oligodendroglioma/

  For patients with oligodendroglioma, knowing their tumors biomarkers can mean the difference between an inaccurate diagnosis and a treatment plan tailored for the best possible outcome. Without biomarker testing, an oligodendroglioma could be misclassified as a different type of glioma, such as astrocytoma, which has a different prognosis and treatment approach. […] Two key biomarkers define oligodendrogliomas. […] The 1p/19q chromosomal co-deletion is the loss of the short (p) arm of chromosome 1 and the long (q) arm of chromosome 19. This co-deletion is required for a definitive oligodendroglioma diagnosis. […] Treatment for oligodendroglioma depends on several factors, including the tumors grade, size, location, and symptoms. […] When safe to do so, the primary treatment for oligodendroglioma is surgical resection to remove as much of the tumor as safely possible.

• #107 Oligodendroglioma: Symptoms, Treatment & Prognosis

  https://my.clevelandclinic.org/health/diseases/21191-oligodendroglioma

  Oligodendrogliomas are treatable, but not technically curable, tumors. The most likely approach to treating oligodendroglioma is to remove the whole tumor (or as much of it as possible) and then your care team determines if chemotherapy, radiation therapy or a combination of these are necessary to eradicate any remaining cancer cells.

• #108 Oligodendroghoma | North Bristol NHS Trust

  https://www.nbt.nhs.uk/bnog/bnog-treatments/oligodendroghoma

  Oligodendrogliomas are primary glial brain tumours that are divided into grade II and anaplastic grade III tumours (World Health Organization [WHO] criteria). […] Oligodendrogliomas may be diagnosed at any age but occur most commonly in young and middle-aged adults, with a median age at diagnosis of 40-50 years. […] The most common presenting symptom is seizure, observed at diagnosis in as many as half of patients. […] Patients with anaplastic oligodendrogliomas (WHO grade 3) who have loss of heterozygosity on 1p or combined loss of heterozygosity on 1p and 19q survive substantially longer than patients whose tumours lack these genetic changes. […] Treatment options vary from conservative treatment of some patients with serial imaging studies and no intervention to aggressive multimodal treatment including surgical resection, radiotherapy, and chemotherapy in others.

• #109 Treatment and prognosis of IDH-mutant, 1p/19q-codeleted oligodendrogliomas in adults – UpToDate

  https://www.uptodate.com/contents/treatment-and-prognosis-of-idh-mutant-1p-19q-codeleted-oligodendrogliomas-in-adults/print

  The treatment and prognosis of grade 2 and 3 IDH-mutant, 1p/19q-codeleted oligodendrogliomas will be reviewed here. […] Surgery provides tissue to establish the diagnosis and is used to relieve symptoms due to mass effect in patients with suspected diffuse gliomas. As with other gliomas, maximal resection is the preferred approach for oligodendrogliomas, but depending upon the location and extent of the tumor, only a partial resection or even just a biopsy may be safely feasible.

• #110 Oligodendroglioma: Symptoms, Treatment & Prognosis

  https://my.clevelandclinic.org/health/diseases/21191-oligodendroglioma

  Oligodendrogliomas are treatable, but not technically curable, tumors. The most likely approach to treating oligodendroglioma is to remove the whole tumor (or as much of it as possible) and then your care team determines if chemotherapy, radiation therapy or a combination of these are necessary to eradicate any remaining cancer cells.

• #111 What Is Oligodendroglioma?

  https://www.rwjbh.org/treatment-care/neuroscience/neurology/conditions/oligodendroglioma/

  To diagnose oligodendroglioma, the following tests may be performed: Neurological exam, Imaging (Computed tomography (CT), Magnetic resonance imaging (MRI), Electroencephalogram), Blood workup, Stereotactic Biopsy, in selected individuals. […] These tumors are treated with surgery, and then with a combination of chemotherapy and radiation.

• #112 Oligodendroglioma | Brain (and spinal cord) tumours | Cancer Research UK

  https://www.cancerresearchuk.org/about-cancer/brain-tumours/types/oligodendroglioma

  You have tests to diagnose an oligodendroglioma. Your doctor checks the size of the tumour and its location. This helps your doctor plan your treatment. […] Oligodendrogliomas are put into groups based on how quickly they are likely to grow. This is called the grade. […] Surgery is usually the first treatment you have. The exact type of surgery you have depends on where the tumour is and how big it is. […] Your doctor might monitor you with regular MRI scans. This is called active monitoring. […] You might have radiotherapy straight after surgery if: doctors can see tumour left behind after surgery; you are over 40 years old. […] Surgery is the main treatment for high grade oligodendroglioma. A specialist doctor called neurosurgeon removes as much of the tumour as possible. […] Your treatment depends on what treatment you have already had. You might have a combination of: chemotherapy with lomustine, temozolomide or PCV; more surgery; more radiotherapy. […] You have regular appointments with your doctor or nurse after treatment finishes. Your doctor examines you at each appointment.

• #113 Oligodendroglioma – brain tumour | Macmillan Cancer Support

  https://www.macmillan.org.uk/cancer-information-and-support/brain-tumour/oligodendroglioma

  Clinical trials also research other areas. These include diagnosis and managing side effects or symptoms. […] After your treatment has finished, you will have regular check-ups, tests and scans. […] You may continue to have some side effects from treatment. […] If you have any symptoms or side effects you are worried about, you can also contact your doctor or nurse between appointments.

• #114 Oligodendroglioma — Low Grade Glioma Registry

  https://gliomaregistry.org/oligodendroglioma

  Regular MRI scans are recommended following the diagnosis of oligodendroglioma, generally at least once per year. Patients with seizures will need to be followed for their seizure medication. […] Prognosis means a prediction of outcome. This information is usually based on information gathered from groups of people with the same disease. It is important to remember these statistics are not individualized. […] Oligodendrogliomas are most common in adults and most often occur between the ages of 20-40. Although these tumors are found in both men and women, they tend to occur more often in men. Oligodendrogliomas are very rare in children under the age of 15.

• #115 Working Through a Life-Changing Rare Brain Tumor Diagnosis – NCI

  https://www.cancer.gov/rare-brain-spine-tumor/blog/2024/working-through-life-changing-rare-brain-tumor-diagnosis

  I did not know that my tumor was a grade 2 oligodendroglioma until after my brain surgery. […] After I had recovered from my surgery, my neuro-oncologist and I agreed we would hold off on further treatment until necessary. I would receive MRI scans every few months to ensure the tumor wasn’t growing. […] In the fall of 2022 nearly two years after my diagnosis the scans showed that my tumor was growing again. […] My most recent scans have not shown any growth. If things change, my doctor has other treatment strategies I can try.

• #116 Oligodendroglioma – American Brain Tumor Association | Learn More

  https://www.abta.org/tumor_types/oligodendroglioma/

  Oligodendrogliomas come from oligodendrocytes, one of the types of cells that make up the supportive, or glial, tissue of the brain. […] Biopsy is typically performed on tumors that are not accessible to confirm the diagnosis and help guide treatment. […] Regular MRI scans are recommended following the diagnosis of oligodendroglioma, generally at least once per year. […] A recurring oligodendroglioma may be treated with surgery, particularly when the time between initial diagnosis and recurrence is extended. In this way, the diagnosis can be updated to reflect any molecular changes that may have occurred over time, whether they be naturally occurring or associated with any treatments including radiation, chemotherapy, or immunotherapy. […] Molecular profiling is the detection of specific genes, proteins, or other molecules in a tumor. This information helps confirm tumor diagnosis, inform treatment options, and predict prognosis. […] Oligodendrogliomas are a type of glioma that have mutations in one of two genes called IDH1 and IDH2 and are missing the two chromosomal arms, 1p and 19q. These tumors are thus named Oligodendroglioma, IDH-mutant, and 1p/19q-codeleted.

• #117 Current diagnosis and treatment of oligodendroglioma in: Neurosurgical Focus Volume 12 Issue 2 (2002) Journals

  https://thejns.org/focus/view/journals/neurosurg-focus/12/2/foc.2002.12.2.3.xml

  The strategies used to diagnose and treat oligodendroglial tumors have changed significantly over the past decade. […] Because of tools such as magnetic resonance imaging, oligodendrogliomas are being diagnosed earlier, and they are being recognized more frequently histologically than in the past. […] Genetic analysis and positron emission tomography may provide data that supplement the standard diagnostic tools. […] Oligodendrogliomas are the first type of brain tumor for which molecular characterization gives important information. The most significant finding is that allelic losses on chromosomes 1p and 19q indicate a favorable response to chemotherapy. […] Molecular characterization of oligodendrogliomas may become a standard practice in the near future.

• #118 Oligodendroglioma | Radiology Reference Article | Radiopaedia.org

  https://radiopaedia.org/articles/oligodendroglioma?lang=us

  Oligodendrogliomas are intracranial tumors that account for 5-25% of all gliomas and 5-10% of all primary intracranial neoplasms. […] They are characterized by IDH mutation and 1p19q codeletion and can be WHO CNS grade 2 or 3. […] As of 2016, however, with the update to the WHO classification of CNS tumors the diagnosis of oligodendroglioma is made by identifying a diffuse infiltrating glioma with IDH mutation and 1p19q codeletion. […] The reliance on molecular markers is, however, not foolproof. […] Histological features are only one aspect of the diagnosis of oligodendroglioma and to formally make the diagnosis, a tumor must be shown to have both IDH-mutation and 1p19q co-deletion. […] By definition oligodendrogliomas should demonstrate IDH mutation (either IDH1 or IDH2) and 1p19q codeletion. […] Treatment is surgical, with adjuvant radiotherapy and chemotherapy.

• #119

  https://link.springer.com/article/10.1007/s00401-015-1424-1

  For nearly a century, the diagnosis and grading of oligodendrogliomas and oligoastrocytomas has been based on histopathology alone. […] Subsequently, this codeletion appeared to not only carry diagnostic, but also prognostic and predictive information, the latter aspect only recently resolved after carefully constructed clinical trials with very long follow-up times. […] It has therefore been suggested that complete 1p/19q codeletion be required for the diagnosis of canonical oligodendroglioma. […] This transition to an integrated morphological and molecular diagnosis may result in the disappearance of oligoastrocytoma as an entity, but brings new challenges as well. […] Meanwhile, smart integration of morphological and molecular information will lead to recognition of biologically much more uniform groups within the spectrum of diffuse gliomas and thereby facilitate tailored treatments for individual patients.

• #120 Oligodendroglioma | Radiology Reference Article | Radiopaedia.org

  https://radiopaedia.org/articles/oligodendroglioma?embed_domain=external.radpair.com%252527%25255B0%25255D%252527%25255B0%25255D&lang=us

  Oligodendrogliomas are intracranial tumors that account for 5-25% of all gliomas and 5-10% of all primary intracranial neoplasms. […] They are characterized by IDH mutation and 1p19q codeletion and can be WHO CNS grade 2 or 3. […] As of 2016, however, with the update to the WHO classification of CNS tumors the diagnosis of oligodendroglioma is made by identifying a diffuse infiltrating glioma with IDH mutation and 1p19q codeletion. […] The reliance on molecular markers is, however, not foolproof. […] To formally make the diagnosis, a tumor must be shown to have both IDH-mutation and 1p19q co-deletion. […] By definition oligodendrogliomas should demonstrate IDH mutation (either IDH1 or IDH2) and 1p19q codeletion. […] Histological features are only one aspect of the diagnosis of oligodendroglioma.

• #121

  https://link.springer.com/article/10.1007/s00401-015-1424-1

  For nearly a century, the diagnosis and grading of oligodendrogliomas and oligoastrocytomas has been based on histopathology alone. […] Subsequently, this codeletion appeared to not only carry diagnostic, but also prognostic and predictive information, the latter aspect only recently resolved after carefully constructed clinical trials with very long follow-up times. […] It has therefore been suggested that complete 1p/19q codeletion be required for the diagnosis of canonical oligodendroglioma. […] This transition to an integrated morphological and molecular diagnosis may result in the disappearance of oligoastrocytoma as an entity, but brings new challenges as well. […] Meanwhile, smart integration of morphological and molecular information will lead to recognition of biologically much more uniform groups within the spectrum of diffuse gliomas and thereby facilitate tailored treatments for individual patients.

• #122 Current diagnosis and treatment of oligodendroglioma in: Neurosurgical Focus Volume 12 Issue 2 (2002) Journals

  https://thejns.org/focus/view/journals/neurosurg-focus/12/2/foc.2002.12.2.3.xml

  The strategies used to diagnose and treat oligodendroglial tumors have changed significantly over the past decade. […] Because of tools such as magnetic resonance imaging, oligodendrogliomas are being diagnosed earlier, and they are being recognized more frequently histologically than in the past. […] Genetic analysis and positron emission tomography may provide data that supplement the standard diagnostic tools. […] Oligodendrogliomas are the first type of brain tumor for which molecular characterization gives important information. The most significant finding is that allelic losses on chromosomes 1p and 19q indicate a favorable response to chemotherapy. […] Molecular characterization of oligodendrogliomas may become a standard practice in the near future.

• #123 Oligodendroglioma Imaging: Practice Essentials, Computed Tomography, Magnetic Resonance Imaging

  https://emedicine.medscape.com/article/342958-overview

  Contrast enhancement is better seen with MRI than with CT scanning, especially with magnetization-transfer, T1-weighted spin-echo MRI sequences after gadolinium enhancement. The importance of contrast enhancement for the prognosis of these tumors has been emphasized because it seems to be the strongest negative factor affecting survival. […] In enhancing oligodendrogliomas, completely resecting enhancing tissue independently improves outcome, irrespective of histologic grade or genetic status. This finding supports aggressive resection and may impact treatment planning for patients with these tumors. […] The combined use of extensive molecular profiling and advanced MRI modalities may improve the accuracy of tumor grading, may provide prognostic information, and has the potential to influence treatment decisions.

• #124 Oligodendroglioma Imaging: Practice Essentials, Computed Tomography, Magnetic Resonance Imaging

  https://emedicine.medscape.com/article/342958-overview

  Contrast enhancement is better seen with MRI than with CT scanning, especially with magnetization-transfer, T1-weighted spin-echo MRI sequences after gadolinium enhancement. The importance of contrast enhancement for the prognosis of these tumors has been emphasized because it seems to be the strongest negative factor affecting survival. […] In enhancing oligodendrogliomas, completely resecting enhancing tissue independently improves outcome, irrespective of histologic grade or genetic status. This finding supports aggressive resection and may impact treatment planning for patients with these tumors. […] The combined use of extensive molecular profiling and advanced MRI modalities may improve the accuracy of tumor grading, may provide prognostic information, and has the potential to influence treatment decisions.

• #125

  https://link.springer.com/article/10.1007/s00401-015-1424-1

  The high clinical relevance of 1p/19q loss became clear when this marker appeared to be associated with sensitivity to chemotherapy and improved outcome. […] Application of strict (as opposed to relaxed) histopathological criteria for recognition of oligodendrogliomas results in a higher correlation with 1p/19q codeleted tumors. […] The most promising markers for oligodendroglial tumors are briefly discussed below. […] In conclusion, after almost a century of a histopathologically based classification of CNS tumors, we are now experiencing the transition towards an integrated morphological and molecular definition of diffuse gliomas, with in some situations the clinical relevance of the molecular findings overriding the relevance of the histopathological diagnosis. […] It can be expected that in the updated WHO classification (publication of which is scheduled early in 2016) demonstration of (complete) 1p/19q codeletion will indeed be required for the diagnosis of canonical oligodendroglioma and that the (poorly reproducible) diagnosis of mixed gliomas will largely disappear.

• #126 Oligodendroglioma Imaging: Practice Essentials, Computed Tomography, Magnetic Resonance Imaging

  https://emedicine.medscape.com/article/342958-overview

  Contrast enhancement is better seen with MRI than with CT scanning, especially with magnetization-transfer, T1-weighted spin-echo MRI sequences after gadolinium enhancement. The importance of contrast enhancement for the prognosis of these tumors has been emphasized because it seems to be the strongest negative factor affecting survival. […] In enhancing oligodendrogliomas, completely resecting enhancing tissue independently improves outcome, irrespective of histologic grade or genetic status. This finding supports aggressive resection and may impact treatment planning for patients with these tumors. […] The combined use of extensive molecular profiling and advanced MRI modalities may improve the accuracy of tumor grading, may provide prognostic information, and has the potential to influence treatment decisions.

• #127

  https://link.springer.com/article/10.1007/s00401-015-1424-1

  The high clinical relevance of 1p/19q loss became clear when this marker appeared to be associated with sensitivity to chemotherapy and improved outcome. […] Application of strict (as opposed to relaxed) histopathological criteria for recognition of oligodendrogliomas results in a higher correlation with 1p/19q codeleted tumors. […] The most promising markers for oligodendroglial tumors are briefly discussed below. […] In conclusion, after almost a century of a histopathologically based classification of CNS tumors, we are now experiencing the transition towards an integrated morphological and molecular definition of diffuse gliomas, with in some situations the clinical relevance of the molecular findings overriding the relevance of the histopathological diagnosis. […] It can be expected that in the updated WHO classification (publication of which is scheduled early in 2016) demonstration of (complete) 1p/19q codeletion will indeed be required for the diagnosis of canonical oligodendroglioma and that the (poorly reproducible) diagnosis of mixed gliomas will largely disappear.

• #128

  https://link.springer.com/article/10.1007/s00401-015-1424-1

  The high clinical relevance of 1p/19q loss became clear when this marker appeared to be associated with sensitivity to chemotherapy and improved outcome. […] Application of strict (as opposed to relaxed) histopathological criteria for recognition of oligodendrogliomas results in a higher correlation with 1p/19q codeleted tumors. […] The most promising markers for oligodendroglial tumors are briefly discussed below. […] In conclusion, after almost a century of a histopathologically based classification of CNS tumors, we are now experiencing the transition towards an integrated morphological and molecular definition of diffuse gliomas, with in some situations the clinical relevance of the molecular findings overriding the relevance of the histopathological diagnosis. […] It can be expected that in the updated WHO classification (publication of which is scheduled early in 2016) demonstration of (complete) 1p/19q codeletion will indeed be required for the diagnosis of canonical oligodendroglioma and that the (poorly reproducible) diagnosis of mixed gliomas will largely disappear.

Zobacz więcej